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Introduction 
 
 
“Depression” by Szuzsanna Szegedi 
 
 
 
“A conceptually novel antidepressant that acted 
rapidly and safely in a high proportion of patients would almost 
certainly become the world’s bestselling drug.” 
(Wong and Licinio, 2004) 
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 1.1 Preface 
Depression is ranked as the fourth leading cause of disease burden worldwide and is expected 
to become the second most disabling disorder by 2010 (Üstün et al., 2004; Simon, 2003). 
Currently available antidepressant drugs are safe and effective, but shortcomings range from a 
delayed onset of action to a significant rate of non-responders. As mood disorders are 
associated with a significant risk for suicide, the latency until the onset of antidepressant 
efficacy makes a more rapid action a desirable attribute for novel antidepressants (Nemeroff 
and Owens, 2002). Therefore, intense attention is currently being given to the identification of 
potential novel drug targets. Both, genetic determinants and environmental factors act 
together to predispose to, or on the other hand protect against psychiatric diseases like 
depression, and they are influencing an individual’s response to pharmacological treatment 
(for review see: Lesch, 2004).  
A previous hypothesis-free approach to identify novel antidepressant-responsive genes was 
performed: To analyse the interaction between genes, behaviour and response to psychoactive 
substances, Sillaber et al. used antidepressant-responsive DBA/2OlaHsd mice to characterise 
their behaviour under basal conditions and after chronic antidepressant treatment (Sillaber et 
al, 2007, submitted). In this study the antidepressant paroxetine, a selective serotonin reuptake 
inhibitor (SSRI) commonly and effectively used to treat clinical depression and anxiety 
disorders, was administered. Genechip microarray analysis was applied for large-scale gene 
expression profiling in the hippocampus in a separate cohort of mice to investigate 
antidepressant-induced changes in gene expression (Sillaber et al, 2007, submitted). The 
hippocampus, receiving serotonergic input, was investigated because of its key role in the 
coordination of behavioural and neuroendocrine responses to stress and its implication in 
stress-related disorders including anxiety disorders and depression (Djavadian, 2004). 
Work of the thesis: 
Selected genes of the microarray analysis, which are potentially involved in pathways of 
affective disorders, could be validated by in situ hybridisation. In a second step the in vivo 
analysis of the distinct gene function, especially of previously unknown genes, was 
performed. Finally, we aimed at transferring our animal data to the clinical situation and 
analysed single nucleotide polymorphisms (SNP) in our genes of interest in cohorts of 
depressive patients. The principal object of the thesis was the identification and detailed 
characterisation (in vitro and in vivo) of novel genes involved in the mechanisms of action of 
antidepressant treatment, thus opening new avenues for discovering new drug targets of 
depressive disorders. 
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1.2 Depressive disorders 
Depression is a multifactorial psychiatric disease, which affects up to 20% of the population 
across the world, and has profound social and economic consequences. It is a recurring, 
chronic and potentially life-threatening disorder with a variable combination of symptoms 
(Berton and Nestler, 2006). Patients suffering from major depression exhibit not only low or 
depressed mood, but also sleep or psychomotor disturbances, low self-esteem, anhedonia, 
reduced food intake and body-weight dysregulation, withdrawal from activities, impaired 
concentration, and finally suicidal tendency (for review see Wong and Licinio, 2001; Nestler 
et al., 2002). In the general population, suicide is one of the leading causes of death among 
adults and it has been estimated that 50-80% of completed suicides are associated with mood 
disorders. About 15% of patients suffering from depressive disorder commit suicide (Kasper 
et al., 1996).  
Unfortunately, we still do not understand the underlying pathophysiology of depression; as 
though there have been various hypotheses related to environmental, genetic and biological 
factors (Rosenzweig-Lipson et al., 2006). Since the serendipitous discovery of the first 
effective antidepressants, monoamine oxidase inhibitors and tricyclic antidepressants 
respectively, the discussion about the possible pathophysiology of depression has been 
dominated by the so-called monoamine hypothesis, which postulates a deficit in noradrenaline 
and/or serotonin in distinct regions in the brain of depressed patients (Hindmarch, 2002).  
Another prominent biological model for depression comprises the dysfunction of the 
hypothalamic-pituitary-adrenal (HPA) axis (Holsboer, 2000). The body’s physiological 
reaction to stressful situations comprises the fast activation of the adrenomedullary system 
(catecholamine release) and the activation of the HPA axis. This secondary stress response is 
slower and characterised by the final release of corticosteroids from the adrenal cortex (see 
figure 1)(de Kloet et al., 2005; Korte, 2001).  
Moreover, there is a large body of evidence implicating that depression is substantially 
influenced by genetic factors and that the genetic component is highly complex and polygenic 
(Fava and Kendler, 2000; Ising and Holsboer, 2006). This makes depression a highly heritable 
disorder (up to 70%), but the search for specific genes that confer this risk has not been very 
successful (Nestler et al., 2002; Lesch, 2004). Due to the complexity of the disease it is likely 
that many genes are possibly involved in the development and there are only very few 
examples of psychiatric illnesses known to be inherited in a strictly Mendelian fashion so far 
(Burmeister, 1999). In addition, individual vulnerability to depression is only partly genetic, 
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 with environmental factors like stress or trauma also being important contributors (Nestler et 
al., 2002). 
Despite this lack of knowledge regarding the underlying pathophysiology of depression there 
are already effective treatment strategies available for this disorder. 
 
 
 
 
 
 
 
 
 
Figure 1 (adapted from Ising and Holsboer, 2006): Model for normal and impaired regulation of the 
hypothalamic-pituitary-adrenocortical axis. CRH = corticotrophin-releasing hormone; AVP = arginin-
vasopressin; POMC = pro-opiomelanocortin; ACTH = adrenocorticotropic hormone. 
In stressful situations CRH and AVP are secreted from neurons of the hypothalamus. They are transported to 
the anterior pituitary through the portal blood vessel system and stimulate the secretion of stored ACTH from
corticotrope cells. ACTH in turn stimulates the adrenal cortex to release glucocorticoids, in particular cortisol 
(human) or corticosterone (rodents). Cortisol/corticosterone is a major stress hormone and has effects on 
many tissues in the body, including the brain. It acts at two types of receptors - mineralocorticoid receptors 
and glucocorticoid receptors. When the organism is persistently exposed to stress, these hormones can be 
pathogenic.  
Impaired corticosteroid signalling results in an attenuation of the negative feedback inhibition of CRH, AVP 
and ACTH, which can lead to chronically elevated levels of cortisol/corticosterone. 
1.3 Antidepressant drugs 
Despite the fact that we still do not understand the aetiology and precise pathophysiology of 
depression, existing antidepressant treatments are safe and effective, but far from ideal. The 
therapeutic effects take several weeks to manifest and these effects are often accompanied by 
unwanted side-effects. Astonishingly enough, fewer than 50% of all patients show full 
remission after treatment with a single antidepressant drug (for review see: Fava and Kendler, 
2000; Nemeroff and Owens, 2002). The history of the treatment of depression started about 
50 years ago, when two classes of substances were discovered by serendipity: the monoamine 
oxidase inhibitors and the tricyclic antidepressants. Most of today’s psychopharmacological 
drugs are based on the mechanism of action of tricyclic antidepressants (TCA), which are 
believed to act by modulating the serotonin and/or noradrenaline system (Wong and Licinio, 
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2001). Currently available antidepressants are mediating their effects by increasing the 
monoamine neurotransmission: (1) by blocking the reuptake or inhibiting the metabolisation 
of the neurotransmitter(s) or (2) by blocking receptors that secondarily increase the signal 
transduction through other receptors, stimulate the release of neurotransmitters or increase the 
neuronal firing rate (Delgado, 2004). This generation of antidepressant drugs can be classified 
in selective serotonin reuptake inhibitors (SSRIs), noradrenaline reuptake inhibitors (NRIs), 
serotonin and noradrenaline reuptake inhibitors (SNRI) and noradrenaline and dopamine 
reuptake inhibitors (NDRIs) (Yadid et al., 2000). Unlike TCA, most of these drugs lack 
affinity for other neurotransmitter receptors, like muscarinic receptors, and their application 
improved the side effect profile and safety of antidepressants (Lucki and O'Leary, 2004). 
However, these substances effect the targeted neurotransmitter systems within hours, whereas 
the effects on mood need weeks to manifest (Wong and Licinio, 2001). These findings imply 
that it is not the monoaminergic signalling and the reuptake inhibition per se but rather yet 
unknown long-term neuroadaptive changes that may underlie these therapeutic effects 
(Boehm et al., 2006). 
Besides the monoamine hypothesis of depression, another well accepted hypothesis has been 
developed, which relates aberrant stress hormone dysregulation to the causality of depression 
(Holsboer, 2000). A major focus of the investigation of the relationship between stress and 
neurobiological changes seen in mental disorders has been the hypothalamic-pituitary-adrenal 
(HPA) axis, both as a marker of the stress response and as a mediator of additional 
downstream pathophysiologic changes (Mello et al., 2003). According to Holsboer and 
Barden, there is considerable evidence that HPA dysregulation is causally implicated in the 
onset of depression and that mechanisms of action of antidepressant drugs include actions on 
the HPA system (Holsboer and Barden, 1996). Therefore great interest is given on the 
development of antagonists for the CRH receptors type 1 and 2, two key players in the HPA-
axis pathway. Other possible antidepressant drug targets within the HPA system are 
vasopressin and glucocorticoid receptors (e.g. glucocorticoid receptor antagonists) (Berton 
and Nestler, 2006; Clark et al., 2007).  
Furthermore, hopeful candidates in the focus of the search for novel antidepressant drugs are 
for example the endocannabinoid system, the neurokinin system, opioid receptors, cytokines, 
histone deacetylase inhibitors and neurotrophic factors (for a detailed review see: Berton and 
Nestler, 2006). 
Regardless these innovative approaches, SSRIs are generally acknowledged to be the first-line 
pharmacological treatment for depression at the moment (Nemeroff, 2007).  
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 For the treatment of severe and treatment-resistant depression, electroconvulsive seizure 
therapy (ECT), in which a generalized epileptic seizure is provoked by electrical stimulation 
of the brain, has a proven therapeutic application (Frey et al., 2001). Despite the efficacy of 
electroconvulsive seizure as a non-chemical antidepressant treatment, the mechanism of 
action remains still unclear (Newton et al., 2006). But there is growing evidence that the 
effects of ECT could be mediated by increasing neurogenesis (the birth of new neurons) 
(Madsen et al., 2000; Altar et al., 2004; Duman and Monteggia, 2006; Newton et al., 2006; 
Ploski et al., 2006). Adult neurogenesis, especially in the dentate gyrus of the hippocampus, 
might be implicated in the aetiology and treatment of depression. It has already been shown 
that stress can be associated with morphometric brain changes, neuronal atrophy, and reduced 
neurogenesis in the dentate gyrus. On the other hand, all antidepressant drugs studied to date, 
including substances of various classes, ECT and behavioural treatments increase 
neurogenesis in the hippocampal dentate gyrus (Duman et al., 2001; Drew and Hen, 2007; 
Paizanis et al., 2007). 
 
1.4 The hippocampus, depression and neurogenesis 
One region of high interest in mood disorder research is the hippocampus as receiving input 
about the “external world” and the homeostatic and emotional “internal world” (Buzsaki, 
1996). The hippocampal dentate gyrus receives the principal afferent input about the external 
world from the entorhinal cortex via the perforant pathway (see figure 2). CA3 neurons in 
turn receive their main input from the dentate gyrus via the mossy fibres. The CA1 represents 
the last stage in the intrahippocampal trisynaptic loop and is the major target of CA3 
pyramidal cell axons, the Schaffer collaterals. The pathway from CA1 to the subiculum and 
on to the entorhinal cortex forms the principal hippocampal output (Freund and Buzsaki, 
1996). Moreover, the hippocampus receives input from the amygdala and the claustrum, the 
septal complex and the supramammillary area, the hypothalamus, thalamus and the brainstem. 
The hippocampus, in turn projects to the septal nuclei, the thalamus, the mamillary and 
amygdaloid complexes and the striatum (Rosene and Van Hoesen, 1987). The hippocampal 
formation is part of the limbic system, which is a major centre for emotion formation and 
processing, for memory, and for learning. Therefore, limbic structures might serve as a link 
between the stress system and neuropsychiatric disorders (Smith and Vale, 2006). 
Additionally, the hippocampus plays a role in modulating body physiology, including the 
activity of the HPA axis, the immune system, blood pressure, and reproductive function. It 
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has been proposed that the hippocampus acts, in parallel with the amygdala, to modulate body 
physiology in response to cognitive stimuli (for review see: Lathe, 2001). 
 
 
 
 
 
 
Figure 2 (adapted from http://www.bristol.ac.uk/Depts/Synaptic/info/pathway/figs/hippocampus.gif):  
The hippocampal dentate gyrus (DG) receives the major afferent input from the entorhinal cortex (EC) via 
the perforant path. The granule cells of the dentate gyrus in turn send their axons (the mossy fibers) to 
innervate the CA3 region. The pyramidal neurons of the CA3 region project via the Schaffer collaterals to the 
CA1 pyramidal neurons. The principal output of the hippocampus finally forms the connection of the CA1 to 
the subiculum (Sb) and on to the entorhinal cortex (Morris and Johnston, 1995). 
The hippocampus is one of the most sensitive and plastic regions in the brain. Both physical 
and psychosocial stress cause adaptive plasticity in the brain, like suppression of neurogenesis 
in the dentate gyrus (McEwen, 2000b; Malberg, 2004). The hippocampal dentate gyrus is one 
of the only two brain structures known to retain the capability to produce new neurons in 
adulthood (Christie and Cameron, 2006; Drew and Hen, 2007). The function of adult 
neurogenesis is not yet well understood, but it has been hypothesised that the decrease and 
increase of neurogenesis in the hippocampal formation are important features associated with 
depressive episodes (Jacobs et al., 2000; Paizanis et al., 2007). Already existing studies 
observed dysfunction or significant reduction of the volume of the hippocampus in patients 
with depression or post-traumatic stress disorder (Sheline et al., 1996; Bremner et al., 2000; 
Sapolsky, 2000; MacQueen et al., 2003; Malberg, 2004). Moreover, brain regions of 
depressed patients, such as the hippocampus, show altered activity patterns in functional 
magnetic resonance imaging (fMRI) and positron emission tomography (PET) (McEwen, 
2006).  
Regarding the time delay for the onset of action of antidepressant treatment, it is very likely 
that adaptations of gene and protein expression could contribute to the therapeutic effect of 
antidepressants. In respect of the opposing actions of stress and antidepressant treatment on 
hippocampal neurogenesis, multiple studies investigate the regulation and function of 
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 neurotrophic factors like brain-derived neurotrophic factor (BDNF) in depression and 
treatment (Duman and Monteggia, 2006). BDNF synthesis in the hippocampus is suppressed 
by stress, at least partially through a sustained modification of chromatin structure. Essentially 
all antidepressant drugs increase BDNF synthesis and signalling in the prefrontal cortex and 
hippocampus. Neurotrophic factors are seen as tools in the activity-dependent modulation of 
neuronal plasticity and could therefore contribute to the therapeutic benefit of antidepressants 
(for review see : Castren et al., 2007). 
One technology capable of identifying underlying pathways in diseases or genes affected by 
antidepressant treatment is gene expression profiling (Boehm et al., 2006). Unbiased 
approaches like microarray analysis are able to uncover novel pathways and changes in gene 
expression levels, which are yet unknown to be involved in disorders like depression. 
 
1.5 Animal models of depression 
Studying the neurobiological mechanisms underlying depression and the therapeutic effects of 
antidepressant drugs on the human brain is quite difficult for various reasons, including 
ethical issues. Moreover, factors like the genetic and environmental prehistory of the patients 
can hardly be controlled for and are difficult to quantify. Therefore, subjects cannot be 
randomised to treatment groups (Shively, 1998). For those reasons, animal models are 
essential tools to study parameters that have been implicated in the neurobiology of 
depression in humans (Cryan et al., 2002). Animal models of human diseases should fulfil 
three criteria: construct validity, predictive validity and face validity. High construct validity 
is achieved when both, the features of depression that are modelled and the behaviour in the 
model are homologous and can be unambiguously interpreted. Further, the modelled feature 
should have an empirical and theoretical relation to depression. Predictive validity is attained 
when a model correctly identifies diverse antidepressant substances and when the treatment 
effect in the model correlates to the effects in the clinical situation. Face validity is given 
when the behaviour and the specific symptoms exhibited by the animal model are similar to 
the human condition (Willner, 1984; McArthur and Borsini, 2006). A forth criterion was 
established by Geyer and Markou in 1995: the aetiological validity. This concept is related to 
the causes of human disease. As causes of mood disorders are seldom known, the validity is 
limited to the hypothesis regarding the possible underlying aetiology (Geyer and Markou, 
1995). Some symptoms of major depression are impossible to model in rodents, like thoughts 
of death or suicide and feelings of worthlessness or guilt, while other symptoms like changes 
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in appetite or weight gain and psychomotor agitation or slowness of movements can be 
observed in animals (Cryan and Holmes, 2005). 
There are various existing models and approaches to model affective disorders and to assess 
the activity of potential therapeutics in mice. Many models are based on genetically modified 
mice, like serotonin or noradrenaline receptor or transporter knockout mice. Many of these 
modified mouse strains have been generated, largely because of known associations between 
the targeted gene and antidepressant action or the pathology of depression (Cryan and 
Mombereau, 2004). The limiting factors in knockout mice are the time consuming generation, 
which allows no high throughput approaches, and compensatory gene regulation after the 
knockout, a factor which can not be properly controlled for and which may influence the 
observed phenotype. Another approach is the use of specific inbred mouse strains like the 
DBA/2 strain. They display a high level of innate anxiety-like behaviour (Ohl et al., 2003; 
Yilmazer-Hanke et al., 2003) and show changes in stress-induced hormone levels (Thoeringer 
et al., 2007) and, therefore, might be suitable to investigate the effects of antidepressant-like 
substances. 
Behavioural paradigms that aim at modelling depression- and anxiety-related phenotypes and 
investigate the potential antidepressant-like effects of novel substances often involve exposure 
to stressful situations. Exposure to persisting stress and trauma has been shown to be one of 
the main predisposing factors to depression. Among those paradigms are the forced swim test, 
the tail suspension test, the learned helplessness paradigm, maternal deprivation or chronic 
mild stress (for review see: Cryan and Slattery, 2007). The probably most frequently used test 
is the Porsolt’s forced swim test (FST) (Porsolt et al., 1977). In this test, rodents are placed in 
a cylinder filled with water, which they cannot escape from. Passive or immobile behaviour 
(floating) is thought to reflect depressive-like behaviour (Porsolt et al., 1977). Antidepressant 
drugs increase the active (swimming, struggling) and decrease the passive (floating) coping 
strategies of mice or rats in this paradigm (Cryan and Slattery, 2007).  
Taken together, despite the difficulties to create an ideal model of depressive disorder, a 
number of different animal models show substantial construct validity and have been widely 
used (Cryan and Slattery, 2007). 
 
1.6 Gene expression studies in mood disorders 
Microarray analysis offers the possibility to screen nearly all genes expressed in a distinct 
tissue or to investigate the changes in gene expression levels associated with antidepressant 
treatments. Therefore, in the last years this technology has been increasingly used to study 
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 polygenic and multifactorial diseases, like psychiatric disorders (Sequeira and Turecki, 2006). 
An increasing number of pharmacogenomic studies have been conducted to reveal the 
molecular pathways underlying the effects of antidepressant drugs: Drigues et al. examined 
the gene expression profile in the hippocampus in rats after chronic treatment with three 
different antidepressants and exposure to the forced swim test (Drigues et al., 2003). Wong et 
al. studied the hypothalamic gene expression in rats after treatment with the tricyclic 
antidepressant imipramine and the herbal product St. John’s worth (Wong et al., 2004). Two 
other groups investigated the effects of electroconvulsive seizure on gene expression levels in 
the rat frontal cortex and hippocampus (Altar et al., 2004; Ploski et al., 2006). Conti et al. 
performed microarray analysis in seven different rat brain regions following three 
antidepressant treatments: electroconvulsive seizure, sleep deprivation and fluoxetine (Conti 
et al., 2007). Until now there is only a small number of microarray studies conducted in mice. 
Boehm et al. for example analysed the subchronic (4 days) and chronic (28 days) effects of a 
tricyclic antidepressant on gene expression in the nucleus accumbens of mice (Boehm et al., 
2006). Another study integrates brain gene expression data from mice (acutely treated with a 
stimulant, and/or the mood stabilizer valproate) with human data (genetic studies in post-
mortem brains) to identify genes involved in bipolar disorders (Ogden et al., 2004). 
Microarray analyses are preferably performed in animals as this allows controlling for various 
conditions, like drug application or environment, and opens the possibility to use genetically 
more homogenous individuals (Sillaber et al., submitted). 
 
1.7 A hypothesis-free approach to identify novel antidepressant-responsive genes in 
the mouse brain 
By means of a reverse pharmacological approach Sillaber et al. aimed at determining 
alterations of hippocampal gene expression in DBA/2OlaHsd mice after chronic 
antidepressant treatment with paroxetine, a selective serotonin reuptake inhibitor (Sillaber et 
al., submitted). Paroxetine is a common and widely used antidepressant drug. The chronic 
treatment was chosen to mimic the clinical situation, in which the antidepressant effects of 
drugs need several weeks to manifest. Four parallel groups of mice were treated chronically 
with either water or paroxetine by oral gavaging (twice daily, 10 mg/kg, 28 days). In two 
groups potential behavioural changes induced by the treatment were assessed, in the other two 
groups paroxetine-induced gene expression alterations in the whole hippocampus were 
investigated by means of microarray analysis. Four hours after the last treatment three 
different behavioural tests were performed: the forced swim test (FST), the modified hole 
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board (mHB) and the dark/light box (DaLi). Antidepressant treatment significantly decreased 
passive stress coping behaviour in the FST. The same decrease in floating behaviour could be 
detected in a retest 18 h after the last administration of the substance. In the mHB and the 
DaLi anxiolytic effects of chronic paroxetine treatment could be shown, as the paroxetine-
treated animals spend significantly more time on the exposed board in the middle of the mHB 
and in the lit compartment of the DaLi. 
The groups taken for gene expression profiling were sacrificed 4 hours after the last treatment, 
then the hippocampus was dissected and antidepressant-induced gene expression changes 
were examined using three different microarray chips (CodeLink, Affymetrix and the house-
intern MPI-Chip). The underlying hypothesis stated that genes, which showed altered mRNA 
expression levels, could be involved in the mechanism of action of paroxetine.  
For the present thesis, eleven genes out of the created list of all regulated genes of the three 
microarrays were chosen (see table 1) to further validate the results by in situ hybridisation 
studies. Selection criteria were among others the known distribution of the gene in behaviour-
relevant brain regions or the relation to depression-relevant genes. After validation, the most 
promising candidates were examined with respect to their role in mediating the 
antidepressant-like effects of paroxetine in vivo. 
 
 
Symbol Name Fold-Regulation 
(on one or two 
platforms) 
Confirmation by
in situ 
hybridisation 
Acvr1 Activin receptor, IA + 1,31 
+ 1,43 
yes 
Cckbr Cholecystokinin B receptor - 1,46 yes 
Chrm1 Cholinergic receptor, muscarinic 1, CNS - 1,32 no 
Gabrd Gamma-aminobutyric acid (GABA-A) receptor, 
subunit delta 
- 1,56 
- 1,61 
yes 
Gmeb1 Glucocorticoid modulatory element binding protein 1 + 1,34 no 
Grp Gastrin releasing peptide + 1,79 yes 
Inha Inhibin alpha - 1,36 yes 
Inhba Activin βA/Inhibin βA + 2,87 
+ 2,7 
yes 
Nr3c1 Nuclear receptor subfamily 3, group C, member 1 - 1,36 yes 
Penk1 Preproenkephalin 1 + 3,04 
+ 2,75 
yes 
Plat Plasminogen activator, tissue + 1,46 yes 
 
 
Table 1: List of selected genes 
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1.8 Scope of the thesis 
As illustrated in the introduction, mood disorders have profoundly deleterious consequences 
on well-being and their toll on economic productivity and quality of life matches that of heart 
disease. Both, genetic determinants and environmental factors act together to predispose to, or 
protect against, psychiatric diseases, like depression, and they are influencing an individual’s 
response to pharmacological treatment. Currently available antidepressant drugs are safe and 
effective, but they are not directly targeting at the underlying pathophysiology of depression. 
Therefore, intense attention is currently being given to the identification of potential novel 
drug targets. The studies presented in this thesis all together aim at identifying such potential 
novel drug targets by investigating the following objectives: 
 
(1) Validation of distinct genes out of an existing microarray by in situ hybridisation to 
prove the induced gene regulation by chronic antidepressant treatment with paroxetine 
(2) Investigation of the time course of gene expression regulation of selected genes 
(3) In vivo analysis of the role of the selected genes in the mechanism of action of 
antidepressant treatment  
 
In project 1 the antidepressant-induced gene expression regulation of eleven different genes 
is validated by in situ hybridisation. Nine out of the eleven genes could be confirmed to be 
regulated in different regions of the mouse brain. These results represent the basis for the 
following experiments: in project 2 the regional and temporal specifity of the gene regulation 
of three validated candidate genes is described. The mice were treated acutely, subchronically 
and chronically with paroxetine in order to investigate the correlation between the onset of 
action of the antidepressant drug and the onset of gene regulation. In project 3 the 
antidepressant-like effects of one of the most promising genes out of the microarray (activin 
βA) were investigated by administration of the protein into two different brain regions of 
mice. To further clarify the neurobiological mechanisms underlying the outcoming 
antidepressant-like effects of the protein, we performed electrophysiological tests. 
Additionally, we wanted to know whether the candidate gene identified might also play a role 
in affective disorders, or in the clinical phenotype and treatment response. Therefore, 
corresponding genetic alterations in patients were compared to our data. Project 4 focuses on 
the in vivo behavioural analysis of a second gene, the gastrin releasing peptide. The effects of 
a stereotactic infusion of the peptide in to the hippocampus were investigated in specific 
depression and anxiety-related paradigms. 
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In consideration of the heterogeneity of the questioning and research objectives each project 
will be introduced and discussed separately. 
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 2.1 Animals and housing conditions 
Experiments were carried out with male DBA/2OlaHsd mice (except project 3, experiment 2, 
3 and 4) from Harlan Winkelmann (Borchen, Germany) or with male DBA/2Ico mice (project 
3, experiment 2 and 3) or male Bl6 mice (project 3, experiment 4) from Charles River 
Laboratories (France or Sulzfeld, Germany). The animals were between 4-8 weeks old on the 
day of arrival. All animals were housed in groups of 4 until an age of 8 weeks, then they were 
singly housed in standard cages (45 cm×25 cm×20 cm) under a 12L:12D cycle (lights on at 
7:00) and constant temperature (23±2°C) conditions. Food and water were provided ad 
libitum. The experiments were carried out at the animal facility of the Max Planck Institute of 
Psychiatry in Munich, Germany, and started when mice attained a minimum weight of 25 g 
and were between 10-14 weeks (except project 3, experiment 2 and 3) or 16 weeks (project 3, 
experiment 2 and 3). In project 3, experiment 4 mice were 6-8 weeks old when the 
experiments were performed. 
The experiments were carried out in accordance with European Communities Council 
Directive 86/609/EEC. All efforts were made to minimize animal suffering during the 
experiments. The protocols were approved by the committee for the Care and Use of 
Laboratory Animals of the Government of Upper Bavaria, Germany.  
 
2.2 Drug application 
Chronic antidepressant treatment 
Animals were randomly distributed to the vehicle or paroxetine treatment group. Paroxetine 
(Seroxat) was obtained from GlaxoSmithKline (Munich, Germany) and was diluted in water 
to a final concentration of 1 mg/ml. The drug (10 mg/kg) or vehicle (water) was given orally 
by gavage twice per day over a period of 28 days. On the last day, the animals were treated in 
the morning at 8:00 and were sacrificed 4 h later. After decapitation, brains were removed, 
frozen in isopentane at –40°C and stored at –80°C for in situ hybridisation studies. 
 
Acute and subchronic antidepressant treatment  
Animals were randomly distributed to the vehicle or paroxetine treatment group. Paroxetine 
(10 mg/kg) or vehicle (water) was given orally by gavage. Animals were treated once (acute 
treatment schedule) or for 7 days (subchronic treatment schedule). In both cases the animals 
received their only/last treatment in the morning at 8:00 and were sacrificed 4 h later. After 
decapitation, brains were removed, frozen in isopentane at –40°C and stored at –80°C for in 
situ hybridisation studies. 
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2.3 Surgery: Intracerebral application of substances 
Mice were anesthetized with pentobarbital sodium diluted 1:20 in 0,9% NaCl (80 mg/kg 
bodyweight, i.p., Narcoren, Rhone Merieux, Paupheim, Germany). The animals were placed 
in a stereotactic apparatus (Stoelting Co., Wood Dale, USA). Stainless steel guide cannulas 
(Hamilton, 23 gauges) were bilaterally implanted under local anaesthesia with lidocaine 
(Xylocain, Astra GmbH, Wedel, Germany). The coordinates for the amygdala and the 
hippocampal dentate gyrus relative to bregma were the following (project 3): -1,0 mm 
anterior-posterior, ±3,1 mm lateral and –1,8 mm dorsoventral and –1,4 mm anterior-posterior, 
± 1,0 mm lateral and -1,1 mm dorsoventral (according to the Paxinos and Watson brain atlas). 
The cannulas in project 4 were placed at coordinates relative to the bregma –1,5 mm anterior-
posterior, ±1,0 mm lateral and -1,5 mm dorsoventral. After surgery the animals recovered for 
14 days before the experiment started. 
Mice were randomly distributed into two groups to be bilaterally infused. In project 3 they 
received either recombinant human/mouse/rat activin A (1 μg/side; carrier free; R&D 
systems, Minneapolis, MN USA) in 0,1% BSA in PBS or vehicle (0,1% BSA in PBS) (as 
described previously Dow et al., 2005). In project 4 we administered either human gastrin 
releasing peptide (1 μg/side; Bachem) in 0,9% saline or vehicle (0,9% saline). A total volume 
of 1 μl was infused and injections were made over 1 min with injection cannulas (Hamilton, 
31 gauges) that extended 1 mm (dentate gyrus and project 4) and 1,2 mm (amygdala) beyond 
the tip of the guide cannula. The injection cannulas were left in place for additional 1 min to 
allow for diffusion of injectate. During experimental manipulation the animals were not under 
anaesthesia and hand-held. Correct cannula placement was determined by post mortem 
histological verification. Mice with misplaced cannulas were excluded from the final analysis. 
 
2.4 In situ hybridisation analysis 
Frozen brains were sectioned coronally at -20°C in a cryostat microtome at 16 μm. The 
sections were thaw-mounted on superfrost slides, dried at 32°C and kept at -80°C. In situ 
hybridisation using a 35S-UTP labelled ribonucleotide probe was performed as described 
previously (Schmidt et al., 2002). Briefly, for riboprobe in situ hybridisation sections were 
fixed in 4% paraformaldehyde and acetylated in 0.25% acetic anhydride in 0.1 M 
triethanolamine/HCl. Subsequently, brain sections were dehydrated in increasing 
concentrations of ethanol. Tissue sections (4 brain sections per slide) were saturated with 100 
μl of hybridisation buffer containing approximately 1x106 cpm 35S-UTP labelled riboprobe. 
Brain sections were coverslipped and incubated overnight at 55°C. The following day the 
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 sections were rinsed in 2xSSC (standard saline citrate), treated with RNAse A (20 mg/l) and 
washed in increasingly stringent SSC solutions at room temperature. Finally sections were 
washed in 0.1xSSC for 1 h at 65°C and dehydrated through increasing concentrations of 
alcohol. 
The tissue plasminogen activator (Plat) cDNA, the delta subunit of the GABA-A receptor 
(Gabrd) cDNA, the gastrin releasing peptide (Grp) cDNA and the activin βA (Inhba) cDNA 
were generated by PCR amplification from mouse hippocampal tissue and subsequent cloned 
into a pCR®II-TOPO® vector (Invitrogen). The used primers are listed in table 2. The cDNA 
templates for the genes including T7 and SP6 promotors for sense and antisense riboprobe in 
vitro transcription were generated by PCR amplification from the vector using a T7 primer 
(5’-GAA TTG TAA TAC GAC TCA CTA TAG GGC GAA TTG-3’) and a SP6 primer (5’-
CCA AGC TAT TTA GGT GAC ACT ATA GAA TAC T-3’). The pGEM vector for activin 
receptor IA (Acvr1, 470 bp) in situ hybridisation was generously provided by the lab of D. 
Huylebroeck (Verschueren et al., 1995). The following vectors came from the microarray 
clone bibliography of the Max Planck Institute of Psychiatry, Munich: For preproenkephalin 1 
(Penk1), cholecystokinin B receptor (Cckbr) and muscarinic cholinergic receptor 1 (Chrm1) 
in situ hybridisation the templates were generated of a linearised pT7T3D vector, whereas the 
template of glucocorticoid modulatory element binding protein 1 (Gmeb1) was generated out 
of a pT7T3D-PacI vector. The template for inhibin alpha (Inha) was derived from a pCMV-
SPORT 2 vector. Finally, the glucocorticoid receptor probe (GR, 1250 bp) in a pCR®II-
TOPO® vector was kindly provided by the research group of Dr. Deussing of the Max Planck 
Institute of Psychiatry. Both antisense and sense 35S-UTP labelled ribonucleotide probes were 
tested on mouse brain tissue. Absence of label after hybridisation with radiolabelled sense 
probe confirmed the specifity of the antisense probe signal.  
The slides were apposed to Kodak Biomax MR films (Eastman Kodak Co., Rochester, NY) 
and developed. Autoradiographs were digitized, and relative expression was determined by 
computer-assisted optical densitometry (Scion Image, Scion Corporation, Frederic, USA). 
The mean of the measurements of 4 different brain slices was calculated from each animal. 
The data were analysed blindly, always subtracting the background signal of a nearby 
structure not expressing the gene of interest from the measurements. 
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Gene Primer sequence Length GC-amount (%) Product lenght (bp) 
Plat upstream 5‘-ATG AGG CAT CGT CTC CAT TC-3‘ 20-mer 50 410 bp 
Plat downstream 5‘-CCT TTT AGG CGC ATC TTC TG-3‘ 20-mer 50 410 bp 
Gabrd upstream 5‘-TGG CTT AAT GGA GGG CTA TG-3‘ 20-mer 50 379 bp 
Gabrd downstream 5‘-GTA CTT GGC GAG GTC CAT GT-3‘ 20-mer 55 379 bp 
Grp upstream 5‘-CAC GGT CCT GGC TAA GAT GT-3‘ 20-mer 55 387 bp 
Grp downstream 5‘-GGG TTT TGT TTT GCT CCT TG-3‘ 20-mer 45 387 bp 
Inhba upstream 5‘-TGG ATG GAG ATG GGA AGA AG-3‘ 20-mer 50 508 bp 
Inhba downstream 5‘-TCC ATT TTC TCT GGG ACC TG-3‘ 20-mer 50 508 bp 
 
 
Table 2: List of used primers 
2.5 Behavioural test paradigms 
Porsolt forced swim test (FST) 
The forced swim test was applied in this thesis as it is the most commonly used experimental 
paradigm to assess antidepressant-like properties of compounds, due to its ability to detect 
activity in a broad spectrum of clinically effective antidepressants (Cryan and Mombereau, 
2004). Three behavioural patterns of the animals are classified in this test: floating 
(interpreted as despair), swimming (seen as neutral behaviour) or struggling (interpreted as 
escape behaviour) (Ohl, 2005). Mice received 15 min (project 3) or 30 min (project 4) before 
the first trial of the forced swim test a single bilateral infusion of either vehicle or activin 
A/gastrin releasing peptide. Each animal was placed into a beaker (diameter: 13 cm, height: 
24 cm) filled with water (temperature 25±1°C) to a height of 15 cm for a test period of 5 min. 
The parameters swimming, struggling (vigorous escape-oriented activity), and floating 
(immobile posture with only small movements to keep balance) were scored by a trained 
observer blind to the treatment. After the performance mice were removed from the water and 
dried with a towel. The animals in project 4 (Grp) were immediately sacrificed after the first 
testing and brains were processed for in situ hybridisation analysis (see 2.4).  
In order to investigate the effects of a first FST exposure under vehicle or activin A treatment 
on the stress-coping strategy, in project 3 all animals were retested 24 h after the infusion. 
Animal were immediately sacrificed after the second trial of the FST, brains were removed, 
frozen in isopentane at –40°C and stored at –80°C for histological localization or in situ 
hybridisation studies.  
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 Modified hole board (mHB) 
As we were interested to get a comprehensive overview on behavioural changes under mild-
stressful conditions and to detect changes in locomotor activity we performed the modified 
hole board test (see for details Ohl et al., 2001) in project 3. The apparatus consisted of a gray 
PVC box (100x50x50 cm) in the middle of which a gray PVC board (60x20 cm) with 23 
holes (1,5x0,5 cm) covered by lids is placed, thus representing the central area of an open 
field. Mice received a single infusion of vehicle or activin A and were tested in the mHB 20 h 
after the treatment. The animals were placed always in the same corner of the outer area of the 
test apparatus for a test period of 5 min each. The following test parameters were scored 
during the test period: board visits, rearing, grooming behaviour, stretched attends and total 
covered distance. Animals were immediately sacrificed after the test, brains were removed, 
frozen in isopentane at –40°C and stored at –80°C for histological localization or in situ 
hybridisation studies.  
 
Elevated plus maze (EPM) 
To assess changes in anxiety-related behaviour in project 4, we performed the elevated plus 
maze test, which is used as a rodent test of anxiety, in a separate cohort of animals. The 
elevated plus maze consisted of two opposing open arms (30x5x0,5 cm) and two opposing 
enclosed arms (30x5x15 cm) of gray PVC which were connected by a central platform (5x5 
cm) shaping a plus sign. Animals were placed 30 min after a single bilateral infusion of either 
vehicle or Grp in the center of the plus maze and were allowed to explore it for 5 minutes. 
Time spent in the open arms, stretching and rearing behaviour as well as number of head dips 
were recorded (Rodgers and Dalvi, 1997). 
 
Open field  
In order to exclude behavioural changes due to alterations in the locomotor activity of mice in 
project 4 we performed the open field test 15 min after the elevated plus maze. Open field 
arenas (50x50x50 cm) were made of gray PVC and evenly illuminated during testing (20 lux). 
General locomotor activity in vehicle and Grp injected mice was recorded for 5 minutes 
(distance traveled) using a video-tracking system (Anymaze 4.20, Stoelting, Illinois, USA). 
 
2.6 Electrophysiology 
Brain slice preparation 
Transverse hippocampal slices (350 μm) were obtained from the brains of adult, 6-8 weeks 
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old mice that were anaesthetized with isoflurane and then decapitated. The brain was rapidly 
removed, and slices were prepared in icy Ringer solution using a vibroslicer. All slices were 
placed in a holding chamber for at least 60 min and were then transferred to a superfusing 
chamber for extracellular or whole-cell recordings. The flow rate of the solution through the 
chamber was 1.5 ml/min. The composition of the solution was 124 mM NaCl, 3 mM KCl, 26 
mM NaHCO3, 2 mM CaCl2, 1 mM MgSO4, 10 mM D-glucose, and 1.25 mM NaH2PO4, 
bubbled with a 95% O2-5% CO2 mixture, and had a final pH of 7.3. All experiments were 
performed at room temperature. 
 
Electrophysiologic recording 
Extracellular recordings of field excitatory postsynaptic potentials (fEPSPs) were obtained 
from the dendritic region of the CA1 region of the hippocampus using glass micropipettes (1-
2 MΩ) filled with superfusion solution. For LTP induction, high-frequency stimulation 
conditioning pulses (100 Hz/1 s) were applied to the Schaffer collateral-commissural 
pathway. Measurements of the slope of the fEPSP were taken between 20 and 80% of the 
peak amplitude. Slopes of fEPSPs were normalized with respect to the 20-min control period 
before tetanic stimulation. 
Isolated NMDA-receptor-mediated EPSCs (NMDA-EPSCs) were measured in the presence 
of 5 μM 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quino–xaline-7-sulphon–amide 
(NBQX) 50 μM picrotoxin and 200 μM 3-aminopropyl(diethoxymethyl)phosphonic acid 
(CGP 35348). Drugs were applied via the superfusion system. Pipettes had a series resistance 
of 4-6 MW, when filled with a solution containing (in mM) K-D-gluconat 130, KCl 5, EGTA 
0.5, MgCl2 2, HEPES 10, D-glucose 5, Na2-phosphocreatine 20 (all from RBI/Sigma, 
Deisenhofen, Germany). Currents were recorded with a switched voltage-clamp amplifier 
(SEC 10L, NPI electronic, Tamm, Germany) with switching frequencies of 60-80 kHz (25% 
duty cycle). Series resistance was monitored continuously and compensated in bridge mode. 
fEPSPs and EPSC were evoked by stimuli (0.033Hz, 4-5 V, 20 μs), delivered via bipolar 
tungsten electrodes insulated to the tip (5-μm tip diameter) and positioned in the Schaffer 
collateral-commissural pathway. The recordings were amplified, filtered (3 kHz), and 
digitized (9 kHz). The digitized responses were stored to disk on a Macintosh computer using 
a data acquisition program. 
 
Substance application 
Either activin A (40 nM) or vehicle (0,1% BSA in PBS) were applied to the perfusion system 
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 for 1 h, then LTP was induced. 
 
2.7 Human genetic association study 
Patient sample 
224 patients (46% male, 54% female; mean age = 48.17; SD = 13.89) were admitted to the 
hospital of the Max Planck Institute of Psychiatry (MPI), Munich/Germany, for treatment of a 
depressive disorder presenting with major depression (88%) or bipolar disorder (12%). Part of 
the patients had participated in previous studies (Künzel et al., 2003). Patients were included 
in the study within 1-3 days of admission, and the diagnosis was ascertained by trained 
psychiatrists according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) 
IV criteria. Patients with depressive disorders due to a medical or neurological condition were 
excluded. Trained raters using the 21-item Hamilton Depression Rating Scale (HAM-D) 
assessed the severity of psychopathology at admission. Patients fulfilling the criteria for at 
least a moderate depressive episode (HAM-D>=14) entered the analysis. All patients were 
Caucasian; ethnicity was recorded using a self-report questionnaire about nationality, first 
language and ethnicity of the subject and of all 4 grandparents. The study was approved by 
the local ethics committee and written informed consent obtained from all subjects. 
 
Combined dex/CRH-test 
Patients underwent combined dexamethasone (dex) / corticotropin releasing hormone (CRH) 
tests at admission (1 to 10 days after admission) and at discharge (10 days or less prior to 
discharge). The procedure of the combined dex/CRH tests was described in detail elsewhere 
(Künzel et al., 2003; Heuser et al., 1994; Holsboer et al., 1987; Zobel et al., 2001). Briefly, 
1.5 mg dexamethasone is orally administered at 11 p.m. the day before stimulation with 100 
µg human CRH. Blood samples are drawn at 15:00, 15:30, 15:45, 16:00, and 16:15 pm. CRH 
is injected just after the first sample is collected. Plasma ACTH concentrations were analysed 
using an immunometric assay without extraction (Nichols Institute, San Juan Capistrano, CA; 
detection limit 4.0 pg/ml). Plasma cortisol concentrations were determined by 
radioimmunoassay (ICN Biomedicals, Carson, CA; detection limit 0.3 ng/ml).  
 
DNA preparation, SNP selection and genotyping 
At the time of enrolment in the study, 40 ml of EDTA blood were drawn from each patient. 
DNA was extracted from fresh blood using the Puregene® whole blood DNA-extraction kit 
(Gentra Systems Inc; MN). 
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We analysed 40 SNPs in the genes encoding activin A and its receptors. Activin A is a 
homodimer consisting of activin ßA subunits encoded by the gene Inhba. Genes Acvr1, 
Acvr2a and Acvr2b code for Activin receptor IA, Activin receptors IIA and IIB, respectively. 
SNPs located within as well as 10 kb up- and downstream of genes Inhba, Acvr1, Acvr2a and 
Acvr2b as included in the Sentrix Human-1 Genotyping BeadChip and HumanHap300 were 
genotyped using Illumina BeadChip technology (Illumina Inc., San Diego, USA) according to 
the manufacturer’s standard protocols. Information on selected SNPs, their position, quality 
control, and minor allele frequencies are available in table 3. 
 
Gene Chr SNP Position Location HWE MAF CR Alleles 
INHBA 7 rs2237435 41697577 Intron 0,108 0,283 1,000 A/C 
INHBA 7 rs2237432 41701558 Intron 0,268 0,238 1,000 G/A 
INHBA 7 rs3801158 41705665 Intron 0,723 0,169 1,000 G/C 
INHBA 7 rs2877098 41709818 Promoter 0,078 0,309 1,000 T/C 
INHBA 7 rs2007475 41713081 Promoter 0,684 0,449 0,992 A/G 
ACVR1 2 rs12997 158301602 3' UTR 0,370 0,268 0,995 G/A 
ACVR1 2 rs1220133 158311561 Intron 1,000 0,243 1,000 A/G 
ACVR1 2 rs10497189 158333049 Intron 1,000 0,105 1,000 C/T 
ACVR1 2 rs1146037 158342534 Intron 0,211 0,237 0,997 C/T 
ACVR1 2 rs3820742 158344586 Intron 0,210 0,237 1,000 T/C 
ACVR1 2 rs10497190 158347485 Intron 0,264 0,196 1,000 T/C 
ACVR1 2 rs7565550 158362536 Intron 0,363 0,208 1,000 A/C 
ACVR1 2 rs10497191 158375462 Intron 0,249 0,126 1,000 T/C 
ACVR1 2 rs4380178 158376690 Intron 0,307 0,180 1,000 A/G 
ACVR1 2 rs10497192 158379945 Intron 0,808 0,292 1,000 C/T 
ACVR1 2 rs4233672 158400171 Intron 0,458 0,215 1,000 A/G 
ACVR1 2 rs13398650 158402625 Intron 0,173 0,105 1,000 A/G 
ACVR1 2 rs2883605 158404774 Promoter 0,322 0,114 0,992 T/G 
ACVR2A 2 rs1364658 148324277 Intron 0,905 0,299 0,997 G/C 
ACVR2A 2 rs6747792 148327997 Intron 0,298 0,215 1,000 G/T 
ACVR2A 2 rs1895694 148336215 Intron 0,606 0,413 1,000 G/A 
ACVR2A 2 rs929939 148343997 Intron 0,815 0,311 0,997 A/C 
ACVR2A 2 rs12987286 148380037 Intron 0,812 0,301 1,000 T/G 
ACVR2A 2 rs1469211 148383304 Intron 0,298 0,215 1,000 A/G 
ACVR2A 2 rs3768689 148386243 Intron 0,905 0,304 0,995 C/G 
ACVR2A 2 rs3820716 148396729 Intron 1,000 0,474 1,000 C/T 
ACVR2A 2 rs2303392 148396896 Intron 1,000 0,310 0,990 G/C 
ACVR2B 3 rs3792527 38468215 Promoter 0,603 0,408 1,000 A/G 
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 ACVR2B 3 rs2268753 38475192 Intron 0,677 0,411 0,992 G/A 
ACVR2B 3 rs7431353 38494428 Intron 0,506 0,346 1,000 A/G 
ACVR2B 3 rs4407366 38496428 Intron 0,439 0,348 1,000 C/T 
ACVR2B 3 rs1046048 38499745 Exon/syn 0,916 0,401 0,990 G/A 
ACVR2B 3 rs7374458 38506214 Promoter 0,439 0,348 1,000 T/G 
ACVR2B 3 rs9838614 38512674 Promoter 0,438 0,348 0,997 C/A 
 
 
 
Table 3: Information and quality control of genotyped SNPs. Chr=chromosome; position according to 
genome build hg18; HWE=p-values for deviation from Hardy-Weinberg equilibrium; MAF=minor allele 
frequency; CR=call rate; Alleles=minor/major allele. 
 
Statistical analysis 
For all SNPs exact tests for Hardy-Weinberg Equilibrium were performed (Wigginton et al., 
2005). No SNPs were excluded due to significant deviation from Hardy-Weinberg 
Equilibrium, 3 SNPs were excluded due to a minor allele frequency below 2.5%, and 3 SNPs 
due to a call rate less than 98%, and this resulted in 34 SNPs entering the analysis (table 3). 
The genotype-related effects on the ACTH and cortisol response in dex/CRH tests at 
admission and discharge were assessed by calculation of areas under the curve (AUC) using 
the trapezoid rule. To correct for the effects of gender and age, standardised regression 
residuals corrected for these potential confounder effects were used for the data analysis. We 
tested both allelic and genotypic modes of inheritance. P values were adjusted for multiple 
comparisons by a re-sampling method (100,000 permutations) according to Westfall and 
Young (1993). The level for significance was set at 5%. We also analysed gene-wide 
associations applying the multivariate Fisher-Product Method (FPM) for all SNPs within one 
gene and for all phenotypes tested (ACTH and cortisol response to dex/CRH tests at 
admission and at discharge, respectively). For in-depth analysis of significantly associated 
SNPs we performed repeated measure ANCOVAs with repeated plasma ACTH and cortisol 
values during the dex/CRH test as within subjects factor and genotypes as between subjects 
factors; age and sex were included as covariates. 
To test for genetic interactions we performed an ANCOVA with genotypes of the 2 highest 
associated SNPs as independent and ACTH and cortisol AUC at admission and discharge as 
dependent outcome variables as well as age and gender as covariates. Due to small groups for 
the rare alleles we excluded patients with genotype ‘GG’ (rs2237432) and ‘AA’ (rs1469211) 
from the analyses. 
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Permutation analyses were performed with the program “Permer” (available at 
http://www.wg-permer.org), all other analyses were performed with SPSS (Release 12.01, 
SPSS Inc., Chicago, USA). 
 
2.8 Statistical analysis 
Data analysis 
The commercially available program SPSS 12 was used for statistical analysis. Comparisons 
of two groups were made by unpaired t-test. The level of significance was set at p<0.05. Data 
are presented as mean + SEM. 
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III Results 
 
3.1  Validation of potential antidepressant target genes 
3.2  Transcriptional changes following paroxetine administration are dependent on the 
duration of treatment and the neuroanatomical region 
3.3  Activin βA is induced by chronic paroxetine treatment and exerts antidepressant-like 
effects in vivo 
3.4  Characterisation of behavioural effects of central gastrin releasing peptide 
administration 
 1.  Validation of potential antidepressant target genes 
Besides the modulation of distinct neurotransmitter systems like the monoamines, a major 
component of antidepressant drug action is their impact on the regulation of gene expression 
(Tardito et al., 2006). Therefore an increasing number of hypothesis-free microarray 
experiments is conducted to investigate the association between antidepressant treatment and 
the resulting changes in expression levels of genes, which might be unknown by now to be 
implicated in mood disorders. Sillaber et al. aimed to determine changes in hippocampal gene 
expression in DBA/2OlaHsd mice after chronic antidepressant treatment with paroxetine, a 
selective serotonin reuptake inhibitor (Sillaber et al., submitted). Depending on the cut-off-
level of fold regulation, they found a different number of genes to be significantly regulated in 
the performed microarray: taking a cut-off-level of ±1,2 255 genes were found to be 
regulated, at a cut-off-level of ±1,35 the expression of 69 genes was found to be altered in the 
total hippocampus. Following these results we performed in situ hybridisation studies in order 
to validate distinct genes. Using the in situ hybridisation technique instead of real-time-PCR 
for validation provides the advantage of revealing brain-region specific differences in gene 
expression levels. Among the regulated genes we chose eleven genes (see table 1) which 
seemed promising with respect to the involvement in the pathophysiology and treatment of 
depressive disorders. The selected genes showed different levels and direction of regulation 
after chronic paroxetine treatment. Functionally they belong to different groups, e.g. to 
growth and differentiation or transcription factors or to the opioid system. The following 
genes were elected from the microarray: three genes of the activin family (activin βA, inhibin 
alpha and activin receptor IA). Activin is of growing interest in respect to its neuroprotective 
and potential antidepressant-like effects (Kupershmidt et al., 2007; Dow et al., 2005). The 
widespread distribution in the CNS and the various proposed neuronal functions of the 
cholecystokinin B receptor suggested it as promising candidate for our studies (for review see: 
Crawley and Corwin, 1994). The muscarinic acetylcholine receptor 1 (CNS) was selected due 
to its known implications in various psychiatric diseases like Alzheimer’s disease, anxiety and 
depression (Levey, 1996; File et al., 2000; Chau et al., 2001). Furthermore, the gamma-
aminobutyric acid receptor, subunit delta gene was chosen due to its expression in brain 
regions involved in depression and anxiety like the dentate gyrus of the hippocampus and the 
amygdala (Fujimura et al., 2005; Persohn et al., 1992; Peng et al., 2002). Additionally, we 
were interested in the glucocorticoid modulatory element binding protein 1 and its ability to 
modulate the glucocortocoid receptor regulated gene induction (Oshima and Simons, Jr., 
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1992; Kaul et al., 2000). The gastrin releasing peptide was of high interest in respect to its 
neuropeptidergic function and its possible involvement in neurochemical alterations 
associated with psychiatric disorders (Yamada et al., 2002; Roesler et al., 2006). In addition, 
our interest was laid on the glucocorticoid receptor, which is already well known for its 
central role in the feedback regulation of the HPA-axis (DeRijk et al., 2002). The 
preproenkephalin 1 gene as precursor of several endogenous opioid peptides was analysed 
due to the well-known fact that many stressors interact with the endogenous opiate systems 
(for review see: Vaccarino and Kastin, 2001). Moreover, inhibition of enkephalin degradation 
exerts antidepressant-like effects in different behavioural paradigms (Baamonde et al., 1992; 
Smadja et al., 1995; Jutkiewicz et al., 2006). Finally, we were interested in the tissue 
plasminogen activator gene. Tissue plasminogen activator deficient mice were shown to 
display an impaired response to stress (Pawlak et al., 2003). 
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Activins, inhibins and receptors: We analysed alterations in gene expression levels of activin 
βA, inhibin α and activin receptor IA after chronic oral paroxetine treatment compared to the 
vehicle treated control group. For mRNA levels of activin βA we could detect a significant 
increase in the CA1 and the dentate gyrus region of the hippocampus in the paroxetine-treated 
group (t-test, p<0.05) (figure 3A), whereas we could not observe differences in the CA3 of the 
hippocampus, the cortex and the thalamus (figure 3A). For activin receptor IA mRNA we 
found a significant increase in the CA3 and dentate gyrus of the hippocampus after chronic 
antidepressant treatment (t-test, p<0.05) (figure 3B) and no changes in mRNA levels in the 
CA1 of the hippocampus (figure 3B). The levels of inhibin α mRNA were significantly 
decreased in the dentate gyrus in paroxetine-treated animals (t-test, p<0.05) (figure 3C). 
Figures 3D, E and F show the respective, representative autoradiographs. 
 
 
Figure 3: 
Expression levels of activin βA, activin 
receptor IA (Acvr1a) and inhibin α 
mRNA in various brain regions after 
chronic paroxetine treatment compared 
to the control group. Activin βA mRNA 
in the CA1, CA3, dentate gyrus (DG), 
the cortex (Co) and the thalamus (Thal) 
(A). Activin receptor IA mRNA in the 
CA1, CA3 and the dentate gyrus (DG) of 
the hippocampus (B). Inhibin α mRNA 
in the CA1, CA3, dentate gyrus (DG) and 
the cortex (Co) (C). Representative 
activin βA mRNA (D), activin receptor 
IA mRNA (E) and inhibin α mRNA 
expression autoradiographs (F). n=9 per 
group.  
* significant from control group, p<0.05.
Data are presented as mean + SEM. 
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Cholecystokinin B receptor: The analysis of cholecystokinin B receptor mRNA expression in 
distinct brain regions after chronic paroxetine administration revealed a significant decrease in 
the CA1 and CA3 region of the hippocampus and the cortex compared to the control group (t-
test, p<0.05) (figure 4A). In the dentate gyrus of the hippocampus and the hypothalamus no 
differences were found between both treatment groups (figure 4A). Figure 4B shows the 
respective, representative autoradiograph. 
 
 
Figure 4: 
Expression levels of cholecystokinin B receptor mRNA in the CA1, CA3, dentate gyrus (DG) of the 
hippocampus, the cortex and the hypothalamus (VMHC = ventromedial hypothalamic nucleus, central part) 
(A). Representative cholecystokinin B receptor mRNA expression autoradiographs (B). Vehicle group n=10; 
paroxetine group n=9. * significant from control group, p<0.05. Data are presented as mean + SEM. 
 
Muscarinic acetylcholine receptor 1: For muscarinic acetylcholine receptor 1 mRNA levels 
we could not detect significant differences in the CA1, CA3 and the dentate gyrus of the 
hippocampus between paroxetine and vehicle treated mice (figure 5A). Figure 5B shows the 
respective, representative autoradiograph. 
 
Figure 5: 
Expression levels of muscarinic acetylcholine receptor 1 mRNA in the CA1, CA3 and the dentate gyrus (DG) 
of the hippocampus (A). Representative muscarinic acetylcholine receptor 1 mRNA expression 
autoradiographs (B). Vehicle group n=10; paroxetine group n=9. Data are presented as mean + SEM. 
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 GABAA receptor, subunit delta: After analysis of alterations in expression levels of GABAA 
receptor, subunit delta mRNA we could detect a significant decrease in the dentate gyrus of 
the hippocampus as well as in the cortex (t-test, p<0.05) (figure 6A), whereas no differences 
could be found in mRNA levels in the CA1 region and the thalamus (figure 6A). Figure 6B 
shows the respective, representative autoradiograph. 
 
 
Figure 6: 
Expression levels of GABAA receptor, subunit delta mRNA in the CA1, the dentate gyrus (DG) of the 
hippocampus, the cortex (Co) and the thalamus (Thal) (A). Representative GABAA receptor, subunit delta 
mRNA expression autoradiographs (B). n=9 per group. * significant from control group, p<0.05. Data are
presented as mean + SEM. 
 
Glucocorticoid modulatory element binding protein 1: For Gmeb1 mRNA expression no 
significant differences between treatment groups were revealed in the CA1, CA3 and the 
dentate gyrus of the hippocampus (figure 7A). Figure 7B shows the respective, representative 
autoradiograph. 
 
 
Figure 7: 
Expression levels of the glucocorticoid modulatory element binding protein 1 mRNA in the CA1, CA3 and 
the dentate gyrus (DG) of the hippocampus (A). Representative Gmeb1 mRNA expression autoradiographs 
(B). Vehicle group n=10; paroxetine group n=9. Data are presented as mean + SEM. 
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Gastrin-releasing peptide: In chronically paroxetine-treated mice we could only observe a 
significant upregulation of gastrin-releasing peptide expression levels in the dentate gyrus of 
the hippocampus (t-test, p<0.05) (figure 8A). No differences in mRNA levels could be 
detected in the CA1 and CA3 of the hippocampus, the accessory basal and the lateral nucleus 
of the amygdala (figure 8A). Figure 8B shows the respective, representative autoradiograph. 
 
Figure 8: 
Expression levels of gastrin releasing peptide mRNA in the CA1, CA3, dentate gyrus (DG) of the 
hippocampus and the accessory basal nucleus (AB) and lateral nucleus (LA) of the amygdala (A). 
Representative gastrin-releasing peptide mRNA expression autoradiographs (B). n=9 per group. * significant 
from control group, p<0.05. Data are presented as mean + SEM. 
Glucocorticoid receptor: The expression of the glucocorticoid receptor gene was significantly 
decreased in the dentate gyrus region (t-test, p<0.05) (figure 9A). However, we could not 
identify differences between treatment groups in the CA1 and CA3 region of the 
hippocampus (figure 9A). Figure 9B shows the respective, representative autoradiograph. 
 
Figure 9: 
Expression levels of the glucocorticoid receptor mRNA in the CA1, CA3 and the dentate gyrus (DG) of the 
hippocampus (A). Representative GR mRNA expression autoradiographs (B). n=9 per group. * significant 
from control group, p<0.05 Data are presented as mean + SEM. 
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 Preproenkephalin 1: Analysis of preproenkephalin 1 mRNA in paroxetine- and vehicle-
treated mice brains revealed a significant increase after antidepressant treatment in the dentate 
gyrus of the hippocampus and the amygdala (t-test, p<0.05) (figure 10A): In contrast there 
was no difference in gene expression in the CA1 of the hippocampus (figure 10A). Figure 
10B shows the respective, representative autoradiograph. 
 
 
Figure 10: 
Expression levels of the preproenkephalin 1 mRNA in the CA1, the dentate gyrus (DG) of the hippocampus 
and the amygdala (A). Representative preproenkephalin 1 mRNA expression autoradiographs (B). Vehicle 
group n=10; paroxetine group n=9. * significant from control group, p<0.05. Data are presented as mean + 
SEM. 
 
Tissue plasminogen activator: For tissue plasminogen activator mRNA we could detect a 
significant upregulation in the CA1 and the dentate gyrus of the hippocampus after paroxetine 
administration (t-test, p<0.05) (figure 11A). Both treatment groups did not differ in tissue 
plasminogen activator mRNA levels in the CA3 of the hippocampus and the cortex (figure 
11A). Figure 11B shows the respective, representative autoradiograph. 
 
 
 
Figure 11: 
Expression levels of the tissue plasminogen activator mRNA in the CA1, CA3 and the dentate gyrus (DG) of 
the hippocampus and the cortex (A). Representative plasminogen activator expression mRNA 
autoradiographs (B). n=9 per group. * significant from control group, p<0.05. Data are presented as mean + 
SEM. 
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Discussion 
In this study we were interested in the investigation of novel genes, which are potentially 
implicated in the mechanism of action of the antidepressant paroxetine and accordingly might 
be involved in the pathophysiology of depression. 11 genes were selected from a microarray 
study performed by Sillaber et al. (Sillaber et al., submitted). We were able to validate nine of 
the eleven genes by in situ hybridisation technique. These findings suggest an influence of 
chronic antidepressant treatment on the expression of various genes. Furthermore, by means 
of in situ hybridisation we could not only show alterations in gene expression levels in the 
hippocampus, where tissue for microarray analysis was taken from, but also in other regions, 
which are relevant for anxiety and depression like the amygdala and the cortex. In the 
following, a short review is given on the influence of chronic paroxetine administration on the 
regulation of selected genes and their functions: 
Activins, inhibins and receptors: Corresponding to the paroxetine-induced upregulation of 
activin βA and activin receptor IA mRNA in the microarray analysis we could detect an 
upregulation of both genes in distinct regions of the hippocampus. For activin βA gene 
expression we could show a significant increase in the CA1 and the dentate gyrus of the 
hippocampus, for activin receptor IA expression an upregulation in the CA3 and the dentate 
gyrus after chronic antidepressant treatment. For the inhibin α subunit we could confirm a 
significant mRNA decrease in the dentate gyrus region of the hippocampus. 
Activins and inhibins belong to the transforming growth factor β (TGF-β) family, which are 
known as multifunctional factors (Shi and Massague, 2003; Flanders et al., 1998). Both 
proteins are composed of two subunits. Until now, five β subunits (βA, βB, βC, βD, βE) and 
one single α subunit were identified. Activins are homodimers (βA-βA , βB-βB) or 
heterodimers (βA-βB) of the activin β-subunits, whereas inhibins are heterodimeric proteins 
composed of one β-subunit which is disulfide-linked to a structurally related α-subunit (Gray 
et al., 2005) Regarding the strong regulation of the activin βA subunit, in this thesis we 
focused on activin A consisting of two βA subunits. Activin A exerts its biological activity by 
two different types of receptors, the type I (Acvr1 and Acvr1b) and the type II receptors 
(Acvr2a and Acvr2b) (Florio et al., 2007). Since the discovery of activin in 1986 (Ling et al., 
1986; Vale et al., 1986) it has been demonstrated to exert a broad range of biological effects. 
Originally, activin has been identified as cytokine, neuroendocrine hormone, and growth and 
differentiation factor (Peng and Mukai, 2000; Danila et al., 2002). Activin βA mRNAs were 
detected in the ovary, testis, placenta, adrenal tissue, bone marrow, spleen, spinal cord and the 
brain (Meunier et al., 1988). Several roles of activin in the CNS have been characterised like 
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 neuronal development and protection (Tretter et al., 1996; Iwahori et al., 1997; Trudeau et al., 
1997). Regarding the activity of activin A in the hippocampus, it has already been shown to 
exert neurotrophic effects on cultured hippocampal neurons and furthermore to be involved in 
neural plasticity (Iwahori et al., 1997; Inokuchi et al., 1996; Shoji-Kasai et al., 2007). Activin 
A is not yet mentioned frequently in the context of anxiety and depression, only recently Dow 
et al. could show antidepressant-like effects of activin A infusion into the dentate gyrus, 
whereas infusion into the CA1 region showed no effects (Dow et al., 2005). 
Cholecystokinin B receptor (Cckbr): We were able to validate the results of the microarray 
analysis providing evidence for paroxetine-induced regulation of the Cckb receptor. We 
detected a significant decrease in the CA1 and CA3 region of the hippocampus and the cortex 
in paroxetine-treated animals.  
Cholecystokinin (Cck) is a regulatory peptide hormone originally discovered in the 
gastrointestinal tract, but also present as a neuropeptide throughout the nervous system. The 
biological effects of Cck are mediated by two specific G-protein coupled receptor subtypes, 
designated Cckar and Cckbr (Herranz, 2003). Together with Cck, the structurally related 
gastrin, a peptide hormone of the gastrointestinal system, is also physiological ligand for the 
Cckbr/gastrin receptors (Rehfeld et al., 2007). The major population of central Cck receptors 
are of Cckbr subtype, but it can also be found in areas of the gastrointestinal tract and on 
pancreatic acinar and parietal cells (Hill et al., 1987; Noble and Roques, 1999). The 
widespread distribution of Cckb receptors in the central nervous system is consistent with the 
various proposed functions of neural Cck like a role in the regulation of satiety, in learning 
and memory, analgesia and neuropsychiatric disorders such as anxiety and panic attacks (for 
review see: Crawley and Corwin, 1994). Existing studies could show that activation of the 
brain Cckb receptor induces anxiety and that on the other hand selective receptor antagonists 
produce anxiolytic effects in rats (Singh et al., 1991; Rezayat et al., 2005). 
Bilateral injection of a selective Cckb receptor antagonist into the CA1 region of the dorsal 
hippocampus produced significant anxiolytic behaviour in the elevated plus maze test 
(Rezayat et al., 2005). As paroxetine has also anxiolytic effects, our observed downregulation 
of the Cckb receptor in the CA1 may contribute to this part of its therapeutic action. 
Moreover, there is evidence that the receptor might be implicated in depressive disorders, as 
antagonism of Cckb receptors mediates antidepressant-like effects in the forced swim test in 
mice (Derrien et al., 1994; Hernando et al., 1994). Additionally, data of Cckb receptor 
knockout mice suggest a role for the receptor in the negative feedback control of the opioid 
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system, as deletion of the receptor resulted in an activation of the endogenous opioid system 
(see preproenkephalin 1, page 48) (Pommier et al., 2002).  
Cholinergic receptor, muscarinic 1, CNS (Chrm1): In case of the Chrm1 we could not 
confirm the analysed alterations in mRNA levels in the microarray after paroxetine treatment. 
The neurotransmitter acetylcholine binds to two different types of receptors, one is the family 
of nicotinic receptors and the other one the family of muscarinic receptors. The muscarinic 
acetylcholine receptors (mAChRs) participate in a number of various functions in the 
periphery and brain, like arousal, sensory processing, cognition and motor control (Felder et 
al., 2000). They are belonging to the super family of plasma membrane-bound G-protein 
coupled receptors and five subtypes have been cloned so far (M1-M5) (Kubo et al., 1986; 
Bonner et al., 1987; Bonner et al., 1988). The mAChRs exhibit a remarkable similarity in 
sequence homology and pharmacology across the mammalian species, especially in rat, 
mouse and humans (Bymaster et al., 2003). The muscarinic acetylcholine receptor 1 is not 
widely expressed in the body periphery, but a few studies reported its presence in the 
sympathetic nervous system and the salivary glands (Caulfield and Birdsall, 1998; Levey, 
1993). However, the expression of Chrm1 in the brain is widespread, including the cortex, 
striatum, and the hippocampus (Levey, 1993). There is already evidence that the receptor 
might be implicated in psychiatric diseases: several studies have reported the potential effects 
of selective M1 agonists for the treatment of Alzheimer’s disease (Levey, 1996; Fisher et al., 
2003; Caccamo et al., 2006) and File et al. suggest a role for Chrm1 agonists in the dorsal 
hippocampus in mediating anxiolytic-effects (File et al., 2000). Moreover, application of a 
M1 antagonist in the nucleus accumbens of rats elicited antidepressant-like effects in the 
Porsolt forced swim test (Chau et al., 2001). 
Gamma-aminobutyric acid (GABA-A) receptor, subunit delta (Gabrd): In situ hybridisation 
analysis revealed corresponding to the microarray data a significant decrease in GABAA 
receptor, subunit delta mRNA in the dentate gyrus and the cortex after chronic antidepressant 
treatment.  
Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central 
nervous system. The transmitter exerts its physiological actions via two different receptors, 
GABAA and GABAB (Shiah and Yatham, 1998). The GABAA receptor is a ligand-gated 
chloride-ion channel and is composed of five subunits. So far 16 different subunits (α1-6, β1-3, 
γ1-3, δ, ε, π, θ) have been cloned from the mammalian nervous system (Möhler, 2006). 
However, the unique functional and pharmacological profile conferred by each of the various 
subunits is not well understood. GABAA receptors containing the δ subunit are restricted to 
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 extrasynaptic somatic and dendritic membranes (Nusser et al., 1998). An already known 
feature of the subunit delta of GABAA receptors is the sensitivity to neuroactive steroids, 
which have been implicated in the genesis of depression and anxiety disorders (Spigelman et 
al., 2003; Stell et al., 2003; Eser et al., 2006). In the hippocampus, neuroactive steroids seem 
to specifically modulate an inhibitory conductance via δ subunit containing GABAA receptors 
(Stell et al., 2003). GABA itself is already known to be involved in depression (for review 
see: Shiah and Yatham, 1998) and Merali et al. could show a dysregulation of GABAA 
receptors subunits, including the δ subunit, in the frontal cortex of depressed suicide victims 
(Merali et al., 2004). Moreover, the subunit is expressed in brain regions involved in anxiety 
and depression, like the amygdala and the dentate gyrus of the hippocampus (Fujimura et al., 
2005; Persohn et al., 1992; Peng et al., 2002). 
Glucocorticoid modulatory element binding protein 1 (Gmeb1): For the Gmeb1 gene we 
could not validate the microarray data in the analysed regions.  
The glucocorticoid modulatory element binding protein 1 is a highly conserved structure of 
high interest in respect of its multiple activities (Zeng et al., 2000; Chen et al., 2002). It has 
already been identified as part of a 550-kDa heterooligomeric protein complex that binds to 
the glucocorticoid modulatory element (GME), a tyrosine aminotransferase gene sequence 
(Oshima et al., 1995). The binding of Gmeb1 to GME is highly associated with its ability to 
modulate glucocorticoid receptor (GR)-regulated gene induction (Oshima and Simons, 1992; 
Kaul et al., 2000). Additionally, Gmeb1 interacts with CREB-binding protein, which 
coordinates the function of multiple transcription factors (Kaul et al., 2000; Leahy et al., 
1999). Moreover, it has been characterised as a member of a family of transcription factors 
called KDWK proteins or SAND domain proteins (Kaul et al., 2000; Bottomley et al., 2001). 
The SAND domain is found in a number of nuclear proteins, which are known to be involved 
in chromatin-dependant transcriptional control (Bottomley et al., 2001). In other contexts than 
transcriptional activity, Gmeb1 has been found to bind the heat shock protein 27, which is an 
antiapoptotic protein (Thériault et al., 1999; for review see: Garrido et al., 2001). Further, it 
has been identified as being involved in Parvovirus replication (Christensen et al., 1997). The 
highest abundance of Gmeb1 is present in fetal and developing tissues, which suggest a role 
in developmental processes (Zeng et al., 2000). 
Gastrin releasing peptide (Grp): In paroxetine-treated animals we could observe a significant 
upregulation of gastrin releasing peptide mRNA in the dentate gyrus. These results are in line 
with the microarray data. 
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Bombesin is a 14 amino acid peptide isolated in 1971 from the skin of a frog (Anastasi et al., 
1971). Some years later the mammalian 27 amino acid homologous counterpart was 
identified, the gastrin releasing peptide (McDonald et al., 1979; Spindel et al., 1984). The 
expression of Grp mRNA is widespread throughout the brain, with high levels being found in 
the isocortex, the hippocampus, the amygdala, the thalamus and the hypothalamus (Wada et 
al., 1990). The distribution of the gastrin releasing peptide receptor, a member of the G-
protein coupled receptor superfamily, is similar to its ligand (Moody and Merali, 2004). The 
peptide is known as a gastrointestinal hormone, growth factor and neuropeptide (Lebacq-
Verheyden et al., 1988). Moreover, gastrin releasing peptide is supposed to be involved in the 
physiological control of feeding behaviour (Stein and Woods, 1982; Ladenheim et al., 1996; 
Merali et al., 1999; Fekete et al., 2002), in the modulation of emotionally-motivated memory 
(Shumyatsky et al., 2002; Martins et al., 2005), in the mediation and/or modulation of the 
stress response (Kent et al., 1998; Merali et al., 2002), and in the control of hypothalamic-
pituitary-adrenal hormone secretion (Garrido et al., 1998; Garrido et al., 1999; Garrido et al., 
2002). Additionally, there is evidence that Grp and its receptor might also be involved in the 
neurochemical alterations associated with psychiatric disorders like depression and anxiety 
(Yamada et al., 2002; Roesler et al., 2006). Underlining this assumption it has been found that 
Grp infusion into the ventral hippocampus of rats increased extracellular GABA levels in the 
hippocampus (Andrews et al., 2000). The observed Grp increase in the dentate gyrus of 
chronic paroxetine-treated mice might therefore have an influence on hippocampal GABA 
neurotransmission. As antidepressant treatments are supposed to have the ability to increase 
GABA neurotransmission, the regulation of the gastrin releasing peptide might contribute to 
the therapeutical effect of paroxetine (Leung and Xue, 2003). 
Nuclear receptor subfamily 3, group C, member 1 (Nr3c1) / glucocorticoid receptor (GR): 
For the GR gene in situ hybridisation analysis revealed a significant decrease in the dentate 
gyrus of the hippocampus after chronic paroxetine treatment, thus confirming the microarray 
data. 
Under the control of the hypothalamic-pituitary-adrenal axis (HPA axis) cortisol 
(human)/corticosterone (rodent) is secreted from the adrenal cortex following stress exposure. 
Central in the feedback regulation of the HPA-axis are two receptors: the mineralocorticoid 
receptor (MR) and the glucocorticoid receptor (GR). While the MR shows high, the GR 
shows a 10 times lower affinity for cortisol/corticosterone (DeRijk et al., 2002). Once bound 
by the ligand, both receptors dimerize and translocate to the nucleus, where they recruit co-
activators to stimulate gene transcription (de Kloet, 2003). MR is supposed to respond to low, 
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 basal circadian levels of circulating glucocorticoids, whereas GR mediates the feedback 
action of high-stress levels of glucocorticoids to restore disturbances induced by stress. Both 
receptors are highly abundant in the hippocampus, but the GR receptor is additionally more 
ubiquitously expressed in the brain, for instance in the cortex, the brain stem, the amygdala 
and the thalamus (de Kloet et al., 1990). Due to the essential function of GR in the feedback 
loop of the HPA-axis, a malfunction of the receptor has serious consequences. It is already 
well known that one characteristic of depressive disorders is a dysfunctional GR system 
(Barden, 2004). Existing data suggest that the function of the GR is reduced in major 
depression in the absence of clear evidence of a decreased GR expression. Further, 
antidepressant treatment seems to have direct effects on GR, leading to enhanced GR 
expression in animal studies (for review see: Pariante and Miller, 2001). Contrary to this data 
are findings of Brady et al., who investigated the effects of three different antidepressant drug 
classes (SSRIs, monoamine oxidase inhibitors (MAO) and α2-adrenergic receptor 
antagonists) on the expression levels of various genes in the rat brain. The SSRI and the MAO 
failed to alter GR levels in the hippocampus after 2 and 8 weeks of treatment (Brady et al., 
1992). In contrast to these findings is the observed downregulation of GR in our experiment. 
This effect could be due to species or strain differences of the chosen animals, application 
differences or differences in the chemical structure and pharmacology of the administered 
antidepressant. Bjartmar and colleagues demonstrated that chronic treatment with different 
subclasses of antidepressants had different and region-specific effects on the direction of GR 
regulation. They found a significant decrease in GR expression in the dentate gyrus of rats 
after fluoxetine treatment, whereas a 5-HT1A-receptor agonist significantly increased GR 
mRNA levels (Bjartmar et al., 2000). Further elucidation of the molecular and biochemical 
mechanisms involved in GR changes in major depression might lead to new insights into the 
pathophysiology and treatment strategies of affective disorders (Pariante and Miller, 2001).  
Preproenkephalin 1 (Penk1): After analysis of gene expression levels of Penk1 by in situ 
hybridisation we could confirm the microarray results. Penk1 mRNA was upregulated in the 
dentate gyrus and the amygdala of chronically antidepressant-treated mice. 
Endogenous opioid peptides and their receptors are distributed throughout the central nervous 
system and various tissues of the mammalian organism (Janecka et al., 2004). The functions 
of opioid peptides reach from a modulatory role in gastrointestinal, autonomic and endocrine 
functions to the modulation of learning and memory (Akil et al., 1998). The known 
endogenous opioid peptides derive from three distinct protein precursors encoded by the 
proopiomelanocortin (POMC), prodynorphin (Pdyn) and preproenkephalin 1 (Penk1) genes 
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(Chaturvedi, 2003). Seven mature pentapeptides are in turn derived by proteolytic processing 
of Penk1: one copy of leu-enkephalin and six copies of met-enkephalin (Legon et al., 1982). 
The existence of three major opiate receptors has been proven: δ, μ and κ receptors (Kieffer 
and Gaveriaux-Ruff, 2002). Leu- and met-enkephalin have high affinities for δ receptors, ten-
fold lower affinities for μ receptors and marginal affinity for κ receptors (Janecka et al., 
2004). Neurons containing high levels of Penk1 mRNA are predominantly interneurons and 
are distributed in the limbic system like the septum, the hippocampus, the bed nucleus of stria 
terminalis and the amygdala (Chaturvedi, 2003; Wiedenmayer et al., 2002). In the 
hippocampus it has already been shown that high frequency stimulation of the dentate gyrus is 
associated with an increase of preproenkephalin mRNA in the granule cells, suggesting a role 
for hippocampal preproenkephalin in mediating functional plasticity (Roberts et al., 1997). 
Corresponding to these data we found a strong increase in the Penk1 mRNA in the dentate 
gyrus after chronic paroxetine treatment, which is supposed to enhance neurogenesis and 
plasticity in the hippocampus. The observed upregulation of Penk1 in the amygdala might 
contribute to the anxiolytic effects of paroxetine, as previous findings could show a 
potentiation of the anxiolytic effects of benzodiazepine by overexpression of 
preproenkephalin in the amygdala (Kang et al., 2000). Moreover, inhibition of enkephalin 
degrading enzymes was proven to exert antidepressant-like effects in various behavioural 
paradigms (Baamonde et al., 1992; Smadja et al., 1995; Jutkiewicz et al., 2006). The 
antidepressant-like and anxiolytic effects are thought to be mediated through the δ opioid 
receptor (Jutkiewicz, 2007). In contrast, mice deficient in the preproenkephalin gene are more 
anxious compared to wildtype mice, but show no depression-related phenotype (König et al., 
1996; Bilkei-Gorzo et al., 2007). Interestingly, there is a neurobiological link between the 
opioid system and the Cckb receptor (see page 44), as the antidepressant-like effect evoked by 
inhibiting enkephalin degrading enzymes is enhanced by a Cckb receptor antagonists 
(Roques, 2000).  
Plasminogen activator, tissue (Plat): Finally, we were able to validate the microarray data 
regarding the tissue plasminogen activator gene. In situ hybridisation analysis could reveal an 
upregulation in the dentate gyrus after paroxetine administration as well. 
Plasminogen activators are serine proteases that cleave the inactive zymogen plasminogen 
into the active protease plasmin, which is capable of degrading a broad spectrum of substrates 
(Melchor and Strickland, 2005). The primary function of plasmin is degrading fibrin, which is 
involved in blood clotting and activating matrix metalloproteinases that, in turn, 
degrade the extracellular matrix (Collen, 1999). Besides these functions, there is growing 
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 evidence that Plat also plays a role in the CNS (Benchenane et al., 2004). In the adult mouse 
brain tissue plasminogen activator mRNA is highly expressed in regions involved in 
autonomic and endocrine functions (hypothalamus), anxiety (amygdala), and learning and 
memory (hippocampus) (Melchor and Strickland, 2005). In the mouse hippocampus it has 
been reported that Plat converts the precursor proBDNF to the mature BDNF (brain-derived 
neurotrophic factor) by activating plasmin (Pang et al., 2004). Regarding the assumed role of 
the neurotrophic factor BDNF in the pathophysiology of depression and antidepressant 
treatment effects, the paroxetine-induced observed increase of Plat in the hippocampus might 
contribute to the neuroplasticity-enhancing effects of antidepressant drugs (Duman and 
Monteggia, 2006). Investigations about the role of Plat in the amygdala showed a significant 
upregulation of total Plat activity in the amygdala after acute restraint stress (Pawlak et al., 
2003). In a following study it could be revealed that Plat activity in the amygdala is 
upregulated by corticotropin-releasing factor, a major stress neuromodulator (Matys et al., 
2004). In contrast, Plat deficient mice display an impaired response to stress and a 
maladaptive hormonal stress response (Pawlak et al., 2003). These results indicate that Plat 
might play a role in emotional learning and might contribute to the control of hormonal stress 
response.  
 
Taken together we were able to validate nine of eleven genes from the microarray performed 
by Sillaber et al. and could therefore confirm a high reliability of the microarray results. With 
respect to the problems of microarray analysis in general in producing reliable data due to 
many aspects of the analysis, which are error-prone, our validation rate is quite high (Asyali 
et al., 2004). Our data may help to achieve a better understanding of the pharmacological 
action of the selective serotonin reuptake inhibitor paroxetine on various gene expression 
levels and signalling cascades. The knowledge of so far unknown genes, which are associated 
with the mechanism of action of antidepressant drugs might help to improve their efficacy or 
identify novel targets for a better therapy of depressive disorder in the future. 
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2.  Transcriptional changes following paroxetine administration are 
 dependent on the duration of treatment and the neuroanatomical 
 region 
Depressive disorders are among the most prevalent and costly diseases of the central nervous 
system worldwide with a serious impact on the affected peoples quality of life (Üstün et al., 
2004). Despite decades of research in that field, progress in understanding the underlying 
neurobiology is slow, and still relatively little is known about both the disease-relevant 
pathophysiological processes and the mechanisms of action of current treatment strategies. 
Although there already are a number of safe and effective antidepressant drugs available, co-
morbidities, treatment resistance and the latency until the first clinical signs of improvement 
often significantly complicate successful treatment and clinical management of these severe 
and life-threatening disorders. The development of novel antidepressant substances which 
acted rapidly and safely in a high proportion of patients therefore is an unmet need in current 
drug discovery research (Nemeroff and Owens, 2002; Taylor et al., 2005). 
The most widely used antidepressants, originally discovered by serendipity about 50 years 
ago, achieve their effect by targeting monoaminergic neurotransmitter systems and, in 
particular, the serotonergic system. The postulated mechanism of action of selective serotonin 
reuptake inhibitors (SSRIs) is to increase the extracellular levels of serotonin by inhibiting its 
reuptake into the presynaptic cell. Interestingly, antidepressant drugs affect their presumed 
target system already within hours of initial treatment which is in marked contrast to the fact 
that the clinical effects of antidepressants take several weeks to develop. This latency of 
antidepressant drug action strongly supports the hypothesis that antidepressant treatment 
induces complex adaptive changes in brain structures affected by depression, including 
regulation of neural gene expression (Celada et al., 2004). In support of this hypothesis, there 
is growing evidence that chronic, but not acute, treatment with different classes of 
antidepressant drugs increases cell proliferation as well as neurogenesis in the hippocampus 
(for review see: Duman et al., 2001; Malberg, 2004; Paizanis et al., 2007).  
So far, the majority of approaches to investigate the underlying neurobiology of depression 
are hypothesis-driven and are largely based on the presumed effects of existing therapeutic 
agents. Over the last years these approaches were successful in developing a growing number 
of more and more selective drugs targeting brain monoaminergic systems. However, they do 
not allow for the identification of novel and innovative drug targets, which, at best, will 
provide the basis for the development of causal treatment strategies with a more rapid onset of 
antidepressant action in the future. 
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 In order to identify those potential novel target genes unbiased, hypothesis-free approaches 
such as proteomics, large-scale genetic or microarray studies are currently undertaken (for 
review see: Sequeira and Turecki, 2006). For reasons of genetic homogeneity and 
minimisation of confounding variables, such investigations are preferably performed in 
animals. Several pharmacogenomic studies using cDNA microarrays have been conducted 
mostly in rats to uncover the molecular mechanisms underlying the actions of different 
antidepressant drugs, such as fluoxetine (Conti et al., 2007), imipramine (Wong et al., 2004), 
paroxetine and mirtazapine (Landgrebe et al., 2002). However, none of these studies 
investigated whether the applied antidepressant treatment schedule elicited antidepressant-like 
behavioural effects in the animals.  
In an attempt to analyse the interaction between genes, behaviour and response to 
psychoactive substances, Sillaber et al., (submitted) investigated antidepressant-responsive 
genes in the mouse hippocampus by microarray analysis. Antidepressant-responsive 
DBA/2OlaHsd mice were treated for 4 weeks with paroxetine, an SSRI which is commonly 
and effectively used to treat clinical depression and anxiety disorders (Feighner et al., 1993; 
Nemeroff, 1994), thus mimicking the clinical situation. In a first step, Sillaber et al. could 
show that chronic paroxetine treatment exerted clear antidepressant-like effects in specific 
behavioural paradigms, providing the basis for a subsequent hypothesis-free discovery of 
novel genes relevant for the antidepressant efficacy of this drug. Therefore hippocampal brain 
tissue was analysed by means of genechip microarray analysis. Previous findings suggest that 
the behavioural effects of chronic administration of antidepressants may be mediated by the 
stimulation of neurogenesis in the hippocampus (Santarelli et al., 2003), indicating the 
hippocampus as a region of high interest for microarray analyses. 
The present study focuses on the characterisation of three selected genes that have been 
shown to be significantly regulated by chronic paroxetine treatment (Sillaber et al.), namely 
the endogenous opioid precursor preproenkephalin 1 (Penk1), tissue plasminogen activator 
(Plat) and the delta subunit of the GABAA receptor (Gabrd). Penk1 is of high interest due to 
the already known implication of opioids in mood disorders, Plat has been shown to be 
involved in aspects of neuronal plasticity and activation of GABA receptors causes a broad 
range of physiological and behavioural processes. In contrast to the majority of 
pharmacogenomic studies published so far, we were not only interested in validating the 
results obtained by expression profiling (see project 1), but we went further to systematically 
analyse two major questions: 1) the time course and onset of gene expression regulation, i.e. 
whether the genes of interest are regulated acutely, following one week or four weeks of 
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paroxetine administration and 2) the regional specificity of gene expression changes induced 
by paroxetine. The latter aspect takes into account that one of the major needs in the field of 
depression research is a better understanding of the involved neural circuits in the brain. 
Particularly interesting are the circuits that control mood under normal circumstances, that 
mediate abnormalities in mood seen in depression and that are targeted by the molecular and 
cellular effects of antidepressant treatment. Based on the complexity of depressive symptoms, 
it is likely that the pathophysiology of this disorder and the mechanisms by which currently 
available treatments reverse its symptoms, involve numerous brain regions and remodelling of 
neuronal circuits (Yamada 2005).  
Corresponding to the known delayed onset of antidepressant drug action, the most prominent 
effects on gene regulation were observed in the hippocampus following 28 days of paroxetine 
administration (see project 1). The mRNA of the GABAA receptor delta subunit was found to 
be significantly regulated already following 7 days of antidepressant treatment, whereas no 
acute or subchronic effects of paroxetine on the expression of the tissue plasminogen activator 
gene could be observed. The effects of paroxetine on the expression of preproenkephalin were 
shown to be dependent on the duration of treatment: both subchronic and chronic (project 1) 
treatment significantly increased preproenkephalin expression in the hippocampal dentate 
gyrus with the extent of mRNA increase being correlated to the duration of paroxetine 
administration. Additional acute effects of paroxetine on the expression of preproenkephalin 
in the amygdala could be observed; interestingly, the direction of gene regulation after acute 
treatment was in the opposite direction compared to the effects of subchronic and chronic 
treatment. 
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Transcriptional changes of preproenkephalin 1 mRNA following paroxetine are dependent on 
duration of treatment and neuroanatomical region 
Acute treatment with paroxetine significantly downregulated Penk1 mRNA in the amygdala 
(t-test, p<0.05) (figure 12A), whereas no difference could be observed in the CA1 region and 
the dentate gyrus of the hippocampus (figure 12A). 
Both subchronic and chronic paroxetine treatment (see project 1) induced a significant 
increase in preproenkephalin 1 mRNA levels in the dentate gyrus of the hippocampus (t-test, 
p<0.05) (figure 12B). In chronically treated animals, a significant increase in Penk1 mRNA 
could also be observed in the amygdala (project 1, figure 10A).  
 
Figure 12: 
Expression levels of Penk1 mRNA in the hippocampus and the amygdala after acute (A) and subchronic (B) 
paroxetine treatment compared to the control group. Penk1 mRNA in the CA1, dentate gyrus (DG) and the 
medial amygdaloid nucleus, posteroventral part (MePV) (A,B). n=9 per group. * significant from control 
group, p<0.05. Data are presented as mean + SEM. 
 
Downregulation of GABAA receptor subunit delta mRNA after subchronic and chronic 
paroxetine treatment  
Acute treatment with paroxetine did not result in an alteration in the expression level of the 
GABAA receptor subunit delta mRNA in any of the brain regions examined (CA1 and the 
dentate gyrus of the hippocampus, cortex and thalamus) (figure 13A). Subchronic paroxetine 
treatment significantly downregulated GABAA receptor subunit delta mRNA in the dentate 
gyrus of the hippocampus and the CA1 region (t-test, p<0.05) (figure 13B). However, no 
differences could be observed in the cortex and the thalamus (figure 13B). As already 
mentioned before (project 1) after chronic paroxetine administration Gabrd mRNA was 
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significantly decreased in the dentate gyrus of the hippocampus and the cortex when 
compared to the control group (figure 6A).  
Figure 13: 
Expression levels of Gabrd mRNA in the hippocampus, the cortex (Co), and the thalamus (Thal) after acute 
(A) and subchronic (B) paroxetine treatment compared to the control group. n=9 per group. * significant 
from control group, p<0.05. Data are presented as mean + SEM. 
 
Hippocampal tissue plasminogen activator (Plat) mRNA expression is regulated following 
chronic paroxetine treatment 
Neither acute nor subchronic treatment with paroxetine resulted in any change in the 
expression of tissue plasminogen activator mRNA levels in the CA1, CA3 and the dentate 
gyrus of the hippocampus or the cortex (figure 14A and B). 
Chronic paroxetine treatment significantly induced tissue plasminogen activator mRNA levels 
in the CA1 and the dentate gyrus of the hippocampus compared to vehicle treated mice (see 
project 1, figure 11A), whereas no differences were found in the CA3 of the hippocampus and 
the cortex. 
 
Figure 14: 
Expression levels of Plat mRNA in the cortex and the CA1, CA3 and the dentate gyrus (DG) of the hippocampu
after acute (A) and subchronic (B) paroxetine treatment compared to the c
from control group, p<0.05. Data are presented as mean + SEM. 
s 
ontrol group. n=9 per group. * significant 
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The present study revealed the regional and temporal specificity of paroxetine-induced gene 
regulation in the adult mouse brain. Three potential novel antidepressant target genes, Gabrd, 
Penk1 and Plat that previously had been identified in a reverse pharmacological hypothesis-
free approach were shown to be specifically and selectively regulated in different 
neuroanatomical subregions of the hippocampus, the amygdala, the cortex and the thalamus. 
Those brain areas have previously been demonstrated to be affected by changes in blood flow 
or related measures in depressed patients and have been implicated in a neural circuitry of 
mood disorders. As potential target sites of antidepressant action, those neuroanatomical 
regions are of particular interest when investigating the molecular and cellular effects of 
antidepressant treatment (Drevets, 2001). 
Although antidepressants have been used for more than 50 years, knowledge about their 
molecular mechanisms of action is still limited. The same holds true for the neurobiologica
m
o
neuroplastic and complex adaptive effects of antidepressant drugs have begun to challenge the 
hypothesis of depression” (for review see: Millan, 2004; Berton and Nestler, 
id system as an “early response” candidate  
l 
echanisms and pathophysiological processes underlying the development and maintenance 
f human affective disorders. During the last years, more and more findings revealing 
“monoamine 
2006), and two major aspects might now be considered as widely accepted in 
psychopharmacology research: 1) that successful antidepressant treatment strategies result in 
molecular and cellular adaptation processes that are downstream of their presumed acute 
effects on monoaminergic neurotransmission (Vaidya and Duman, 2001) and 2) that given the 
complexity and diversity of depressive symptoms, it is likely that the pathophysiology of the 
disorder and the mechanisms by which successful treatments reverse its symptoms involve 
numerous brain regions interacting in neuronal circuits. 
 
Region-specific regulation of novel antidepressant target genes is dependent on duration of 
paroxetine-treatment: the endogenous opio
The SSRI paroxetine is one of the most widely used antidepressant drugs to treat depression 
and anxiety disorders. Paroxetine acutely enhances serotonergic neurotransmission by the 
potent and selective inhibition of the serotonin transporter (SERT) resulting in a decreased 
neuronal reuptake of serotonin. It has also been shown to be a weak inhibitor of 
norepinephrine reuptake (Nemeroff and Owens, 2003). After acute application peak plasma 
concentrations are reached in humans about five hours after oral administration, whereas 
steady-state plasma concentrations are reached after 7 to 14 days of treatment (Gunasekara et 
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al., 1998). While the preclinical in vivo pharmacology of paroxetine is consistent with its 
primary action as an antagonist of the SERT, the typical delay of 3-5 weeks following 
initiation of antidepressant treatment until a clinical response can be observed has stimulated 
the interest in elucidating the neurochemical and molecular changes that occur following 
chronic antidepressant administration. 
At the level of serotonergic neurotransmission, acute application of SSRIs in rats results in an 
hibition of neuronal firing and reduced release of serotonin (Hjorth and Auerbach, 1994; 
ation 
 (4 weeks) paroxetine treatment (project 1), paralleling 
in
Hjorth and Auerbach, 1996; Hajós et al., 1995). It is assumed that this effect arises from a 
blockade of serotonin reuptake in the raphe nuclei, which is followed by an indirect activ
of somatodentritic 5-HT1A autoreceptors. This receptor activation is thought to counteract the 
enhancing effect of paroxetine on serotonergic neurotransmission. Corresponding to the 
delayed onset of the therapeutic action of paroxetine in treatment of depression, the activation 
of the 5-HT1A autoreceptors become desensitised after approximately two weeks and the 
firing rate of serotonergic neurons returns to normal. Moreover, adaptive changes, like 
decreased responsiveness of synaptic serotonergic receptors, which in turn leads to enhanced 
serotonin release, occur after two to three weeks of treatment as well (Gunasekara et al., 
1998). Those differences between acute and long-term adaptive changes in neurotransmission 
and receptor properties might be responsible for the observed differences in downstream gene 
regulation following increasing duration of treatment. In the present investigation, the three 
novel antidepressant target genes, Gabrd, Penk1 and Plat, were shown to be regulated in the 
mouse hippocampus following chronic
the antidepressant-like behavioural effects in this unbiased study design (Sillaber et al.). 
However, genes that are already regulated following 1 week of paroxetine administration or 
even acutely could be early antidepressant-responsive genes, and, as early players in a 
complex cascade of antidepressant-regulated genes, could be of interest to further investigate. 
We therefore extended our analyses and examined whether Gabrd, Penk1 and Plat are 
regulated in the brains of mice that received the antidepressant for 1 week or acutely. Only 
Penk1 could be shown to be regulated in the mouse amygdala following a single 
administration of paroxetine. Interestingly, the direction of gene regulation after acute 
treatment was in the opposite direction compared to the effects of subchronic and chronic 
treatment: acute treatment resulted in a downregulation of Penk1 mRNA in the amygdala, 
whereas the extent of mRNA increase in the hippocampal dentate gyrus was correlated to the 
duration of paroxetine administration.  
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 The endogenous opioid system and the neuropeptide Penk1 in particular, have already been 
recognized as potential drug target in mood disorders as inhibition of enkephalin degrading 
enzymes proved to exert antidepressant-like effects in various behavioural paradigms 
(Baamonde et al., 1992; Smadja et al., 1995; Jutkiewicz et al., 2006).  
Endogenous opioid peptides are the naturally occurring ligands for opioid receptors and are 
synthesised in the central nervous system and in various glands throughout the body, such as 
the adrenal glands and the pituitary. Opioid peptides function both as neuromodulators and as 
hormones and, therefore generate a variety of physiological effects (Janecka et al., 2004). The 
known endogenous opioid peptides derive from three distinct protein precursors encoded by 
proopiomelanocortin (POMC), prodynorphin (Pdyn) and preproenkephalin 1 (Penk1) genes 
(Akil et al., 1984). The high-affinity δ and μ opioid receptors for the mature pentapeptides 
leu-and met-enkephalin are ubiquitously expressed throughout the brain, including the limbic 
system (Gulya et al., 1986; Moskowitz and Goodman, 1984). Neuropeptides commonly occur 
with, and are complementary to, classic neurotransmitters. (Hökfelt et al., 2003). Penk1-
derived peptides have been shown to inhibit GABA release from inhibitory interneurons in 
in mRNA (Morris and 
the hippocampal formation which, in turn, results in increased excitability of dentate gyrus 
granule cells and hippocampal pyramidal cells (Simmons and Chavkin, 1996). Moreover, it 
has been reported that stimulation of the dentate gyrus or NMDA release in the region of 
granule cell dendrites causes a dramatic increase in preproenkephal
Johnston, 1995). Accordingly, electroconvulsive seizures (ECS) have been shown to increase 
the expression of endogenous opioid peptides in various brain regions, including the 
hypothalamus (Yoshikawa et al., 1985) and the limbic system (Kanamatsu et al., 1986). Even 
if the clinical antidepressant effects of ECS and antidepressant drugs are very similar, their 
presumed mode of action might not necessarily be the same. To the best of our knowledge, 
there is no data on antidepressant-induced modulation of Penk1 expression in the limbic 
system so far. Our finding that paroxetine treatment, either acute, subchronic or chronic 
(project 1), significantly and specifically modulates the expression of Penk1 in the amygdala 
and the hippocampal formation adds further evidence to the potential involvement of the 
endogenous opioid system in mood disorders. Opioids might act as mediators of hippocampal 
plasticity and might be involved in neuroplastic phenomena that are most likely to underlie 
successful antidepressant therapy. 
Another important aspect to discuss is the regional specificity of paroxetine-induced gene 
regulation. Our findings underline the complexity of antidepressant-induced neurobiological 
effects, which are dependent on the neuroanatomical region or duration of treatment. There is 
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only a very limited number of studies investigating region-dependent neurobiological effects 
of antidepressant treatment so far (D'Sa et al., 2005; Serres et al., 2006; Dagestad et al., 2006; 
Conti et al., 2007). Most studies focus on one particular region of interest. However, to 
advance our understanding of the therapeutic actions of antidepressants, we must now extend 
our efforts beyond theories based on dysfunction of selected neuroanatomical regions. While 
many brain regions have been implicated in regulating emotions, we still have a very 
rudimentary understanding of the neural circuitry underlying normal mood and the 
abnormalities in mood that are the hallmark of depression. It is likely that many brain regions 
together mediate the diverse symptoms of depression (Drevets, 2001). Of course, these 
various brain regions operate in a series of highly interacting parallel neuronal circuits.  
 
The delta subunit of the GABAA receptor as antidepressant target gene: potential involvement 
eptor 
ubunits in rat brain (Heninger et al., 1990; Kang and Miller, 1991; Tanay et al., 1996). These 
g a regional heterogeneity that may be implicated in the mechanisms of 
receptor subtype shows a unique pharmacological profile and therefore many drug binding 
of neurosteroids 
We identified the GABAA receptor subunit delta mRNA to be significantly downregulated in 
the hippocampal dentate gyrus following chronic paroxetine treatment (project 1). Validation 
of these data by means of in situ hybridisation provided evidence that the GABAA receptor 
subunit delta mRNA was also downregulated in the cortex of paroxetine-treated mice. We 
could further show that downregulation of Gabrd mRNA in the dentate gyrus was already 
significant following 7 days of treatment. In contrast, acute antidepressant treatment had no 
effects on the expression level of this gene.  
GABAA receptors and GABAergic mechanisms are already known to be directly implicated 
in behavioural and physiological processes (Shiah and Yatham, 1998; Korpi et al., 2002), and 
have been suggested to play a role in human affective disorders (Brambilla et al., 2003). It has 
been reported that chronic administration of antidepressants (i.e. phenelzine and imipramine) 
or benzodiazepines may differentially modulate the gene expression of GABA rec
s
studies showed that the modulation of GABA receptor subunits may vary in different brains 
regions, suggestin
action of antidepressants in mood disorder patients. However, there was no evidence so far 
supporting the GABAA receptor subunit delta mRNA as antidepressant target gene. GABAA 
receptors mediate the majority of fast inhibitory neurotransmission in the brain. They are 
composed of a combination of five different subunits exhibiting specific individual expression 
patterns in distinct brain regions and even in their subcellular localisation. Furthermore, each 
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 sites exist (McKernan and Whiting, 1996; Korpi et al., 2002). Interestingly, GABA receptors 
containing the  subunit are insensitive to diazepam and are located exclusively at 
extrasynaptic sites as shown in the hippocampal dentate gyrus and cerebellum, the thalamus, 
cortical areas and the striatum (Wisden et al., 1992; Fritschy and Möhler, 1995; Pirker et al., 
2000; Sperk et al., 1997). They are tailor made for tonic inhibition, due to their high affinity 
for GABA and slow desensitization kinetics (Möhler, 2006). GABA receptors containing the 
 subunit are the target of neuroactive steroids such as allopregnanolone, 
dehydroepiandrosterone (DHEA) or 3,5-Tetrahydrodeoxycorticosterone (3,5-TH DOC), 
which are synthesised in the central nervous system (Stell et al., 2003). Neuroactive steroids 
are potent modulators of GABAA receptors and specifically enhance a tonic inhibitory 
conductance in hippocampal neurons (for review see: Belelli and Lambert, 2005; Stell et al., 
2003). Additionally, it has been reported that the effects of neuroactive steroids are reduced in 
δ subunit knockout mice (Mihalek et al., 1999; Spigelman et al., 2003). Changes in 
neurosteroid levels are associated with various physiological and pathophysiological 
conditions including stress, pregnancy and postpartum depression as well as ageing. 
Moreover, neurosteroids have been shown to exert potent anxiolytic/antidepressant-like 
effects in different behavioural paradigms: allopregnalonone, for example, exerts 
antidepressant-like effects in the mouse forced swim test (Khisti and Chopde, 2000; Khisti et 
al., 2000). Dysregulation in the neurosteroid response may, therefore, predispose for the 
development of mood disorders (Stell et al., 2003; Girdler and Klatzkin, 2007). Concerning a 
potential role of neurosteroids in mood disorders, the dominant idea emerging from clinical 
and preclinical studies is that neurosteroids could be involved in the pathophysiology of 
affective disorders as well as in the mechanism of action of SSRI (for review see: Brambilla 
et al., 2003; Van Broekhoven and Verkes, 2003; Pinna et al., 2006). Indeed, it was previously 
shown that antidepressant treatment, especially with SSRIs, increases the concentrations of 
neurosteroids in the cerebrospinal fluid or plasma of patients suffering from major depression 
(Uzunova et al., 1998; Ströhle et al., 2002). Moreover, fluoxetine potentiates the 
antidepressive effect of allopregnalonone by enhancing the GABAergic tone but, remarkably, 
not by enhancing serotonergic neurotransmission (Khisti and Chopde, 2000). Our finding that 
paroxetine treatment regulates the expression of the GABAA receptor δ subunit mRNA in the 
mouse hippocampus might therefore add further evidence to the involvement of neurosteroids 
and the Gabrd in the mechanism of action of antidepressant drugs, the more as the  subunit 
was the only GABA receptor subunit that was found to be significantly regulated by 
paroxetine treatment in the microarray analyses (data not shown, Sillaber et al., submitted). 
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The observed changes in the expression level of the GABA receptor  subunit might be 
discussed in the context of altered circulating neurosteroid levels following chronic 
antidepressant treatment. Previous studies revealed a rapid and specific regulation of the  
subunit during the estrous cycle (Maguire and Mody, 2007) and following stress (Maguire 
and Mody, 2007). Those two conditions are known to be associated with changes in brain 
neurosteroid content. However, those experimental conditions are different from our study 
design regarding the variations in circulating neurosteroid concentrations occur regularly 
(during the estrous cycle) or very rapidly (already 30 minutes following acute stress).  
 
Tissue plasminogen activator mediates synaptic plasticity and BDNF action 
The third potential antidepressant target gene in our focus is the tissue plasminogen activator 
(Plat or tPA). Plasminogen activators are serine proteases of tryptic specifity that catalyse the 
conversion of the inactive proenzyme plasminogen into the active serine protease plasmin. 
Plasmin has a very broad spectrum of substrates and is capable of degrading indirectly or 
directly most of the extracellular proteins (Vassalli et al., 1991). The primary substrate of 
active plasmin in the vasculature is fibrin. Plasmin breaks down fibrin clots, aiding in vascular 
patency and haemostasis (Melchor and Strickland, 2005). Beside its fibrinolytic function, 
there is growing evidence that Plat also plays an intriguing role in the CNS (Benchenane et 
al., 2004). It has been shown that Plat is secreted by neurons during neurite outgrowth and 
tissue remodelling. Moreover, several lines of evidence suggest that Plat activity might be 
important for learning-related synaptic plasticity. Baranes et al. could show that Plat 
contributes to the late phase of LTP and induces both axonal elongation and the production of 
new synaptic structures in the hippocampal mossy fibre pathway (Baranes et al., 1998). One 
potential mechanism by which Plat exerts its effects on synaptic growth is the conversion of 
e BDNF precursor to the mature BDNF by activation of plasmin. Such conversion is critical 
r and Strickland, 
th
for late-LTP expression in mouse hippocampus (Pang et al., 2004; Melcho
2005). Taking into account that the precursor and the mature BDNF can have opposite 
biological effects (pro-apoptotic versus neurotrophic effects), proteolytic processing of the 
precursor by the Plat/plasminogen system represents an interesting mechanism to control the 
direction of BDNF action (Teng et al., 2005). The potential implications of the striking degree 
of overlap between the molecular and cellular changes induced by antidepressant treatment 
and the molecular mechanisms of neuroplasticity, especially in synaptic plasticity have been 
reviewed in detail most recently (Pittenger and Duman, 2008). The involvement of Plat in 
synaptic plasticity and the BDNF pathway in particular has encouraged us to study the 
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 antidepressant-induced regulation of Plat expression in more detail. Chronic (see project 1), 
but neither acute nor subchronic treatment with paroxetine resulted in a significant 
upregulation of Plat mRNA in the dentate gyrus and the CA1 area of the hippocampal 
pyramidal cell layer. This paroxetine-induced upregulation of Plat could lead to an increase in 
mature BDNF protein, which, in turn, has been supposed to normalise depression-associated 
dysfunction of neuronal circuits by supporting synaptic and neuronal remodelling and 
increasing hippocampal neurogenesis (Duman and Monteggia, 2006). Interestingly, the well 
described antidepressant-induced upregulation of BDNF has recently been shown to occur 
following chronic (three weeks of treatment), but not acute antidepressant treatment, thus 
paralleling the time course of paroxetine-induced regulation of Plat in the present analysis 
(Khundakar and Zetterstrom, 2006). 
 
In summary, our present study was designed for identifying molecular events downstream of 
direct antidepressant actions on monoamines (i.e. downstream of paroxetine’s direct action on 
serotonine reuptake), thus generating new theories about the pathophysiology of depression 
and the potential action of antidepressant medication. We could confirm and further 
investigate three potential novel antidepressant target genes which previously had been 
identified by means of a hypothesis-free approach (see project 1). The three candidates Penk1, 
Plat and Gabrd show distinct patterns with respect to temporal specificity of gene expression 
regulation, suggesting that there are “early” and “late” responder genes to antidepressant 
treatment: as Penk1 is already regulated following acute and subchronic paroxetine treatment, 
it may represent a novel target for faster onset antidepressant drugs. The Gabrd is crucially 
important for the action of neurosteroids which have been shown to be involved in emotional 
regulation. Plat is a highly interesting antidepressant target gene with respect to its 
involvement in the BDNF pathway and mechanisms of neuroplasticity. 
Furthermore, all three genes show region-specific patterns of antidepressant-induced 
expression changes. This regional specificity underlines the importance to extend our efforts 
eyond theories based on dysfunction of selected neuroanatomical regions and to study b
neuronal circuits when investigating the complex mechanisms by which successful treatments 
might reverse depressive symptoms. Ongoing studies will continue to further elucidate the 
role of the three novel candidate genes in antidepressant action, finally aiming at the 
development of more specific and effective therapeutic interventions with a more rapid onset 
of action in the future. 
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3. Activin βA is induced by chronic paroxetine treatment and exerts 
 antidepressant-like effects in vivo 
Affective disorders are among the leading causes of morbidity and mortality world-wide 
(Kessler et al., 2003; Andlin-Sobocki and Wittchen, 2005). Since the serendipitous discovery 
of tricyclic antidepressants about half a century ago, the lack of a clear understanding of the 
pathophysiological mechanisms underlying depression has prevented the development of 
drugs targeting specific proteins. Theories about the mechanisms of action of currently 
itially act on substrates (e.g. neurotransmitter uptake) considerably 
upstream of yet unknown targets, which are ultimatively responsible for the antidepressant 
effects. In this context one of the major systems postulated to mediate the delayed adaptive 
effects of antidepressants are neurotrophic signalling cascades (Nestler et al., 2002). 
In an unbiased approach to identify potential novel genes and signalling pathways mediating 
antidepressant-like effects, Sillaber et al. (submitted 2007) performed a brain-region specific 
microarray analysis for large-scale gene expression profiling in antidepressant-responsive 
DBA/2OlaHsd mice treated 4 weeks with the SSRI paroxetine. In a first step they could show 
that chronic paroxetine treatment exerted clear antidepressant-like effects in specific 
behavioural tests providing the basis for a subsequent hypothesis-free discovery of novel 
genes relevant for the antidepressant efficacy of paroxetine. Among other interesting potential 
targets, Sillaber and co-workers could show that a group of genes that are involved in 
neurogenesis as well as in neuronal plasticity (e.g. BDNF, Egr1, Egr1 and Stat3) and neuronal 
cell differentiation (e.g. Vimentin) are significantly upregulated by chronic paroxetine 
treatment, supporting the intriguing hypothesis that neurotrophic factors and adult 
neurogenesis play critical roles in mediating the behavioural responses to antidepressants (for 
review see: Duman and Monteggia, 2006). 
One of the genes that was found to be significantly upregulated by chronic paroxetine 
treatment was activin βA (Sillaber et al., 2007). Activins and inhibins are members of the 
transforming growth factor β superfamily and are dimeric proteins composed of α- and/or β- 
available antidepressants have focused primarily on their effects on synaptic 
neurotransmission such as inhibition of neurotransmitter uptake (e.g. selective serotonin 
reuptake inhibitors). Those currently available antidepressant drugs are safe and effective, but 
only less than half of the patients attain complete remission after therapy with a single 
antidepressant drug after 6-8 weeks (Nemeroff and Owens, 2002). Moreover, the vast 
majority of patients does not respond until 3-5 weeks after initiation of the treatment. It has 
been hypothesised that this delay in the onset of action of existing antidepressant drugs is due 
to the fact that they in
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 subunits. Activins are homo- or heterodimers of activin β-subunits, whereas inhibins are 
heterodimeric proteins composed of one β-subunit which is linked to the structurally related 
rain and 
d to detect an upregulation of activin mRNA 
α-subunit by disulfide bounds (for review see: Luisi et al., 2001; Bernard et al., 2001). Activin 
has originally been shown to control many physiological processes such as cell proliferation, 
cell differentiation, immune responses, wound repair and various endocrine activities (for 
review see: Luisi et al., 2001; Munz et al., 1999). Inhibin α, activin βA and activin βB 
mRNAs were detected in a variety of organs: in the bone marrow, kidney, spinal cord and in 
the brain (Meunier et al., 1988). Activin signalling is mediated by two different 
transmembrane receptor serine/threonine kinases (type 1 and type 2 receptors) whose 
expression is relatively widespread, with prominent expression sites in the central nervous 
system (e. g. the hippocampal dentate gyrus and other areas of the limbic system in the case 
of activin type 2 receptors, Acvr2a) (Cameron et al., 1994). Binding of activin to type 2 
receptors (Acvr2a or Acvr2b) is followed by phosphorylation and activation of type 1 
receptors (Acvr1 and Acvr1b), which in turn triggers a transient association and 
phosphorylation of SMAD2 or 3. This leads to a translocation to the nucleus, enabling the 
SMADs to target a variety of DNA binding proteins regulating transcriptional response 
(Pangas and Woodruff, 2000). 
Despite the interesting expression pattern of activin and its receptors in the b
particularly in the limbic system, there is only relatively sparse data on its putative effects on 
central nervous system function focussing on the role of activin A in neuronal development 
and neuroprotection. Activin supports neuron survival in primary cell cultures of rat 
hippocampus (Iwahori et al., 1997) and facilitates neuronal development (Trudeau et al., 
1997). Furthermore, noxious stimuli such as kainic acid lesions of the hippocampus increase 
the expression of activin βA mRNA (Tretter et al., 1996) and infusion of activin A, in turn, 
was shown to reduce neuronal damage after excitotoxic brain injury (Tretter et al., 2000). 
Those neuroprotective properties of activin A are further supported by data from transgenic 
mice (dnActRIB) in which activin signalling is selectively disrupted in limbic brain areas. 
DnActRIB transgenic mice are significantly more vulnerable to the excitotoxin kainic acid 
than their control littermates (Müller et al., 2006). Most recently, Dow et al. described an 
increase of activin βA mRNA in the rat dentate gyrus following chronic electroconvulsive 
seizures. However, the investigators faile
following chronic antidepressant treatment with the SSRI fluoxetine (Dow et al., 2005). 
Given the described neuroprotective properties, activin A is an interesting novel candidate 
gene as antidepressant target. Therefore, we selected – among a variety of other genes 
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regulated in the microarray experiment (Sillaber et al.) – activin A to be investigated in more 
detail and to examine its role in mediating the antidepressant-like effects of paroxetine. In a 
first step, we validated the antidepressant-induced upregulation of activin βA by means of in 
situ hybridisation (see project 1). In this study we additionally intended to examine the time-
course of paroxetine-mediated gene regulation. We then investigated the behavioural effects 
of stereotactic infusion of activin A into the dentate gyrus or the amygdala to determine 
whether activin A exerts region-dependent antidepressant-like or anxiolytic effects in specific 
behavioural paradigms in vivo.  
To further clarify the neurobiological mechanisms underlying the antidepressant-like effects 
of activin A, we studied whether activin A is able to modulate the electrophysiological 
properties of hippocampal neurons. We could show that even nanomolar concentrations of 
activin A significantly block hippocampal LTP, and that this blockade of LTP is not mediated 
via NMDA receptors. As we were finally able to identify genetic variants in the human 
activin signalling pathway that are associated with specific endophenotypes of depression, 
there is strong evidence that the activin system is an interesting candidate system for the 
development of novel antidepressant drugs in the future.  
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Experiment 1: 
Effects of acute and subchronic treatment with paroxetine on activin βA mRNA levels 
Acute paroxetine treatment (10 mg/kg) had no significant effect on activin βA mRNA 
expression levels in the CA1, CA3 or the dentate gyrus of the hippocampus, nor in the cortex 
(figure 15A). In contrary, subchronic treatment with paroxetine resulted in an increase of 
activin βA mRNA levels in the CA1 and the dentate gyrus of the hippocampus as observed 
following chronic treatment (t-test, p<0.05), whereas additionally the activin βA gene was 
significantly downregulated in the CA3 (t-test, p<0.05) (figure 15B). 
 
 
 
Experiment 2: 
Activin A injection into the dentate gyrus resulted in an antidepressant-like effect in the 
Porsolt forced swim test (FST) (Porsolt et al., 1977) 
The forced swim test was applied in this study as it is the most commonly used experimental 
paradigm to assess antidepressant-like properties of compounds (Cryan and Mombereau, 
2004). In rats, generally two trials (one pretreatment-trial before drug application) are 
required to generate a stable immobility readout, whereas for yet unexplained reasons in mice 
one exposure is sufficient after drug application (Cryan and Mombereau, 2004). In our case 
we were interested in investigating the effects of a single FST exposure following vehicle or 
activin A treatment on the stress-coping strategy, so all animals were retested 24 h after the 
infusion. 
Due to a strong upregulation of activin βA in the dentate gyrus of DBA mice after chronic 
Figure 15: 
Expression levels of activin βA mRNA in the CA1, CA3 and the dentate gyrus (DG) of the hippocampus and 
the cortex after acute (A) and subchronic (B) paroxetine treatment compared to the control group. Acute 
treatment n=6, subchronic treatment n=9. * significant from control group, p<0.05. Data are presented as 
mean + SEM. 
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Figure 16: 
on of activin A into the dentate gyrus of the hippocampus produces antidepressant-like effects in 
e treatment, we wanted to examine the behavioural effects of bilateral 
 of activin A into the dentate gyrus. Therefore, we infused activin A (1 
in after 
paroxetin
microinjections
μg/side) or 0,1 % BSA in the dentate gyrus and performed behavioural testing 15 m
the infusion. We could observe a strong antidepressant-like effect of activin A as animals that 
received activin A showed a significant increase in struggling (t-test, p<0.05) and a significant 
decrease in floating behaviour (t-test, p<0.01) with no change in swimming 15 min after 
treatment (figure 16A). The differences between treatment groups in struggling behaviour 
could still be observed 24 h after the activin A infusion (t-test, p<0.05) (figure 16B). 
 
Acute infusi
the forced swim test 15 min after infusion (A), which lasted over 24 h (B). Vehicle group n=5, activin A 
group n=4. Swim=swimming, strug=struggling and float=floating. * significant from control group, p<0.05. 
Data are presented as mean + SEM. 
 
terested in region-specific effects, we decided to investigate the effects of
haviour 15 min after treatment (figure 
As we were in  
bilateral activin A infusion into the amygdala as well. Animals that received activin A showed 
no changes in struggling, floating or swimming be
17A). Only 24 h after treatment we found a tendency that activin A infusion caused an 
increase in swimming (t-test, p=0.056) (figure 17B). 
 
 67
  
Figure 17: 
Animals that received acute bilateral activin A infusion into the amygdala showed no changes in struggling, 
floating or swimming behaviour 15 min after treatment (A). Only 24 h after treatment we found a tendency 
that activin A infusion caused an increase in swimming (B; p=0.056). Vehicle group n=7, activin A group 
n=10. Swim=swimming, strug=struggling and float=floating. Data are presented as mean + SEM. 
 
 
Experiment 3: 
Reduction of anxiety-like behaviour in the modified hole board after activin A injection into 
the amygdala 
The modified hole board was used to get a comprehensive overview on behavioural changes
u stressful conditions and to assess alterations in locomotor activity due to acute 
a
A  
reated animals were observed for the measured time in the exposed area, i.e. on the board, the 
figure 18A) and the number of rearings 
as not significantly changed. Grooming behaviour did not differ between the groups (data 
not shown). 
Activin A infusion into the amygdala revealed a slight but not significant difference between 
activin A- and vehicle treated animals for the measured time in the exposed area, i.e. on the 
board (t-test, p=0.087) (figure 19A). No behavioural changes were observed for the latency 
until the first entry on board or the entries on board (data not shown). Parameters reflecting 
risk assessment or exploration were not significantly different between groups. Activin A 
 
nder mild 
ctivin A treatment. 
fter activin A infusion into the dentate gyrus, no differences between activin A- and vehicle
t
latency until first entry on board or the entries on board (data not shown). Both groups did not 
differ in risk assessment behaviour reflected by the number of stretch attends (data not 
shown). Furthermore, parameters indicating activity and exploration were not significantly 
different between groups: the general locomotor activity during 5 minutes of hole board 
exposure was not altered after activin A treatment (
w
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ent effect on the locomotion of the mice. Dentate gyrus n=4; amygdala n=8. Data are 
SEM. 
rved (data not shown).  
sion into the amygdala revealed a slight but not significant difference between activin A- and 
treatment had no influence on general locomotor activity during 5 minutes of hole board 
exposure (figure 18B). Finally, there was a remarkable but not significant different effect in 
grooming behaviour, activin A treated animals tend to groom less than control animals (t-test, 
p=0.057) (figure 19B). 
 
 
Figure 18: 
Influence of activin A infusion into the dentate gyrus of the hippocampus (A) and the amygdala (B) on 
locomotor activity was measured 20 h after the treatment in the modified hole board. There was no 
significant treatm
presented as mean + 
 
Figure 19: 
20 h after activin A infusion into either the dentate gyrus or the amygdala mice performed the modified hole 
board test. After infusion into the dentate gyrus no differences between activin A- and vehicle treated animals 
could be obse
Activin A infu
vehicle treated animals for the measured time in the exposed area, i.e. on the board (A; p=0.087). Grooming 
behaviour was reduced in activin A treated animals (B; p=0.057). n=8 per group. Data are presented as mean 
+ SEM. 
 
 
 
 Figure 20: 
Effects of activin A on long-term potentiation in the hippocampal CA1 area. HFS=high-frequency 
stimulation. n=8 per group. * significant from control group, p<0.05. Data are presented as mean ± SEM. 
e studied long-term potentiation (LTP) in the Schaffer collateral-
ommissural pathway in acute brain slices. When slices were superfused with activin A 
(40nM), LTP was significantly weaker than under control conditions, at least 60 minutes after 
high-frequency stimulation (t-test, p<0.05) (figure 20). 
 
Experiment 4 (in cooperation with Gerhard Rammes,Max Planck Institut of Psychiatry): 
Activin A blocks hippocampal long-term potentiation 
To assess whether activin A causes alterations in synaptic plasticity in the CA1 region of the 
dorsal hippocampus, w
c
 
 
Experiment 5 (in cooperation with Susanne Lucae, Max Planck Institut of Psychiatry): 
Human genetic association study 
Dex/CRH test 
Three intronic SNPs located in the gene coding for activin A (Inhba) were significantly 
associated with the ACTH response in the dex/CRH test at discharge in a genotypic mode of
inheritance (p
re  
th  
re  
s). Furthermore SNPs of both genes and in the genes Acvr1 and 
inally associated with ACTH and cortisol responses at admission and 
e, but these associations did not withstand correction for multiple testing. 
 
corrected for rs2237432, rs2237435 and rs2877089 = 0.00305, 0.0105 and 0.0452, 
spectively). ACTH and cortisol responses for SNP rs2237432 are presented in figure 21. In
e gene coding for Activin receptor IIA (Acvr2A) 2 SNPs were associated with cortisol
sponse at discharge in an allelic mode of inheritance (pcorrected for rs1469211 and rs6747792
= 0.0489 for both SNP
Acvr2b were nom
discharg
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When testing all SNPs within one gene against a combination of all four phenotypes in an 
ly associated (pgenotypic = 0.00481). FPM-analysis we found the Activin A gene to be high
We tested for genetic interactions of SNPs rs2237432 (Inhba) and rs1469211 (Acvr2a) for all 
4 phenotypes and found nominally significant interaction effects for the ACTH response at 
admission (p = 3.942 x 10-4, Fdf3 = 6.333) and discharge (p = 2.122 x 10-5; Fdf3 = 8.581). 
 
Figure 21: 
Cortisol (A) and ACTH (B) response in the dex/CRH test of depressed in-patients at admission (left) and 
discharge (right) according to rs2237432 genotypes. 
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 Discussion 
Induction of activin βA mRNA after paroxetine treatment 
Based on the data from an unbiased approach to identify novel antidepressant target genes, we 
could show that chronic antidepressant-treatment with paroxetine resulted in a significant 
upregulation of activin βA in the CA1 and the dentate gyrus of the hippocampus (project 1). 
These findings are in line with previous reports demonstrating an upregulation of activin βA 
mRNA in the rat hippocampus after acute and chronic electroconvulsive seizure (ECS), an 
effective treatment for depression (Andreasson and Worley, 1995; Dow et al., 2005; Conti et 
al., 2007). In contrast to our study, Dow et al. could not find an upregulation of activin βA 
mRNA levels in the hippocampus after chronic treatment with desipramine (a norepinephrine 
reuptake inhibitor) or fluoxetine (a serotonin reuptake inhibitor), whereas Conti et al. 
observed a slight increase of activin βA mRNA levels in the hippocampus after two weeks of 
fluoxetine treatment.  
So far there is evidence that activin A, consisting of two activin βA subunits, might play a 
role in neuronal development and neuroprotection. As neuroplastic alterations in the 
hippocampus have been discussed to be involved in the pathophysiology of depression 
(Paizanis et al., 2007), our findings could indicate that activin βA participates in the 
neurotrophic or neuroprotective action of antidepressant treatment. Activin has been shown to 
support survival in primary cell cultures of rat hippocampal neurons (Iwahori et al., 1997) and 
to facilitate neuronal development in amygdala neurons of the rat (Trudeau et al., 1997). 
Daadi et al demonstrated that activin and fibroblast growth factor 2 play a role in regulating 
the fate of the embryonic basal forebrain ventricular zone progenitors (Daadi et al., 1998). In 
addition, activin stimulates somatostatin expression and differentiation of developing ciliary 
ganglion neurons (Coulombe et al., 1993). Furthermore there is evidence that long-term 
n increases activin βA mRNA in vitro in granule cell neurons of the hippocampus 
 and Worley, 1995; Inokuchi et al., 1996). In vivo 
xperiments underline these results: Tretter et al could show an increase of expression of 
ctivin βA mRNA after kainic acid lesions of the hippocampal CA3 region (Tretter et al., 
1996) and in following experiments infusions of recombinant activin A reduced neuronal 
damage after excitotoxic brain injury (Tretter et al., 2000). Inokuchi et al. could show a 
significant induction of the expression of activin βA mRNA as a result of excitotoxic injury as 
well (Inokuchi et al., 1996). In transgenic mice expressing a dominant-negative activin 
receptor 1b blocking the activin signalling, hippocampal neurons were significantly more 
vulnerable to intracerebroventricular injection of the excitotoxin kainic acid than those from 
potentiatio
and in vivo in rat hippocampus (Andreasson
e
a
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control mice (Müller et al., 2006). These findings suggest a role of activin A in the 
exclude the possibility that the 
 of chronic antidepressant drug application, we additionally found a 
neuroprotective action of antidepressant drugs. To 
upregulation of activin βA might lead to formation of inhibin A, which consists of an inhibin 
α and an activin βA subunit, we performed also an in situ hybridisation analysis for inhibin α 
(project 1). The analysis revealed a significant downregulation of inhibin α mRNA in the 
dentate gyrus region of the hippocampus, indicating that the increase in activin βA mRNA 
expression might rather lead to formation of activin A than inhibin A. 
According to the delayed onset of action of antidepressant treatment we could not show any 
differences in the activin βA mRNA levels in the mouse brain after acute paroxetine 
treatment, whereas for subchronic treatment a significant increase of activin βA gene 
expression could be observed in the CA1 and the dentate gyrus region of the hippocampus. 
This is corresponding to the results after chronic administration of paroxetine (project 1). In 
contrast to the effects
significant decrease of activin βA mRNA levels in the CA3 region of the hippocampus. 
 
Infusion of activin A into the dentate gyrus, but not the amygdala, elicits antidepressant-like 
behaviour 
In this study we could show that infusion of the dimeric protein activin A into the dentate 
gyrus of mice resulted in antidepressant-like effects in the forced swim test lasting up to 24 h, 
whereas we could show no such behavioural effects after infusion into the amygdala. The 
provoked behavioural alterations in the forced swim test after hippocampal activin A 
application are in line with a previous study, in which activin A infusion into the dentate 
gyrus resulted in an antidepressant-like phenotype in rats as well (Dow et al., 2005). 
Moreover, they could show that coinfusion of activin A and inhibin A blocked the activin A 
elicited behavioural changes. Inhibin A alone did not alter the phenotype in the FST 
compared to the control group, which clearly supports the hypothesis that activin A and not 
inhibin A might contribute to the therapeutic actions of antidepressant treatment.  
Preclinical and clinical studies have shown that neuronal atrophy and loss might result from 
stress conditions and are possibly involved in the development of depression (for review see: 
Duman et al., 1999). On the other hand, neurotrophic factors like BDNF and neurotrophin-3 
are known to be critical for the survival of neurons (for review see: McAllister et al., 1999) 
and are thought to be implicated in the mechanism of action of antidepressant treatment 
(Nibuya et al., 1995; Shirayama et al., 2002). Interestingly, a single infusion of BDNF into the 
hippocampal dentate gyrus exerted antidepressant-like effects in the FST 3 to 10 days after 
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 substance application (Shirayama et al., 2002). Activin βA has also been shown to hold 
neurotrophic or neuroprotective abilities (Iwahori et al., 1997; Tretter et al., 2000; Müller et 
al., 2006). Moreover, it has been hypothesised that disturbed hippocampal activity could 
underlie some of the depressive symptoms, at least in part, because of loss of synaptic 
contacts, a process that is likely to be reversed by antidepressant drugs (Hajszan et al., 2005). 
Shoji-Kasai and colleagues demonstrated that activin is upregulated during hippocampal long-
term potentiation and increases the number of synaptic contacts as well as the length of 
lation 
to antidepressant-like effects. 
ts of activin A infusion into the amygdala, a region which is richly endowed with 
 investigate 
dendritic spine necks (Shoji-Kasai et al., 2007). Regarding the fast onset of antidepressant-
like effects of activin A after 15 min in the forced swim test, it is not very likely that 
neurotrophic actions or synaptic remodelling are mediating the acute behavioural changes in 
mice. As there are various studies reporting on acute modulation of synaptic transmission by 
neurotrophic factors this could be a possible mechanism underlying the actions of activin as 
well (Levine et al., 1995; Poo, 2001; Müller et al., 2006). Future studies will be needed to 
identify the molecular adaptations underlying the actions of activin A and their trans
in
In order to compare brain area-specific functions of activin A we were additionally interested 
in the effec
activin receptors (Jakeman et al., 1992; Cameron et al., 1994; Funaba et al., 1997) and highly 
involved in mediation of physiological and behavioural responses associated with fear and 
strong emotions (for review see: McEwen, 2005). We could not show antidepressant-like 
effects of activin A application into the amygdala in the forced swim test, but we were able to 
detect slight anxiolytic effects of the protein in the modified hole board test. 
 
Infusion of activin A into the amygdala tend to produce anxiolytic effects 
In the modified hole board a broad spectrum of behaviour patterns can be tested (Ohl et al., 
2001). We were mostly interested in anxiety-like behaviour and locomotor activity of the 
treatment groups. The influence of activin A on the locomotion was determined to
whether the decrease of immobility and the increase of struggling in the FST are due to a 
general effect on locomotor activity. As we could not observe any changes in locomotor 
activity between activin A treated and control animals, we can conclude that the observed 
antidepressant-like effects arise from application of activin A. These findings are in line with 
the results of Dow and colleagues (Dow et al., 2005).  
Interestingly, in contrast to the results of the FST, in the modified hole board infusion of 
activin A into the amygdala turned out to have slight, but not significant, anxiolytic effects, 
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whereas there was no difference in behaviour after activin A injections into the hippocampal 
dentate gyrus compared to vehicle. These data propose a region-specific mechanism of action 
of activin A. The amygdala is considered to be a key brain-region in assigning emotional 
significance to a specific sensory input, and conditions like anxiety are supposed to be linked 
to its abnormal function (Wand, 2005). Animals that received activin A infusion tend to spend 
more time on the exposed inner board of the modified hole board, indicating that the mice 
were less anxious than the vehicle group. Furthermore, the time spent with grooming, which 
is considered as displacement activity in uncertain situations, was slightly reduced (Cohen 
and Price, 1979). Like in the hippocampus, for the amygdala a possible neurotrophic role of 
activin A is suggested, which might support anxiolytic effects (Trudeau et al., 1997). It has 
been already suggested that the stimulation of neurotrophic factors, like BDNF, may also 
prove to arise anxiolytic effects (Gorman, 2003). 
Taken together we could show that activin A exerts distinct behavioural effects, depending on 
the brain region, in which it is injected. Of course, there is need of further studies to elucidate 
the role of activin A in modulating emotional behaviour in more detail. 
 the influence of 
ctivin and its receptors on synaptic activity and plasticity are quite contrary. Inhibition of 
 and collegues could 
the length of dendritic spine necks and 
 
Activin A blocks hippocampal long-term potentiation 
Electrophysiological experiments revealed that nanomolar concentrations of activin A 
significantly block hippocampal long-term potentiation (LTP) in the CA1 region of the mouse 
hippocampus. Additionally, we could exclude that this inhibition is mediated by N-methyl-D-
aspartate (NMDA) receptors, which are normally required for LTP induction in the CA1 
region of the hippocampus (Malenka and Nicoll, 1993). The sparse data on
a
LTP in the hippocampus by activin A has already been reported. Ikegaya
show that activin selectively blocks the induction of LTP evoked by threshold tetanic 
stimulation but not robust LTP elicited by strong tetanic stimulation of the perforant path. 
They proposed that activin plays a role in the decision-making process whether a LTP is 
essential or indefinite (Ikegaya et al., 1997). In contrast to these findings it has been found 
that expression of activin βA subunit mRNA is induced in the dentate gyrus of rats by high 
frequency stimulation of the perforant pathway. In this experiment it could be shown that the 
increase of gene expression was NMDA receptor-dependent (Inokuchi et al., 1996). 
Furthermore, it has been shown that activin increases 
number of synaptic contacts in cultured neurons (Shoji-Kasai et al., 2007). In a recent study of 
Alzheimer and colleagues in transgenic mice expressing a dominant-negative activin IB 
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 receptor in forebrain neurons, a reduced NMDA current response and impaired LTP in the 
CA1 region could be observed, which in turn resulted in impaired synaptic plasticity (Müller 
et al., 2006). Taken together, the studies suggest that activin A plays in interesting role in 
neuronal activity and plasticity in the rodent brain, but the specific function still remains 
unclear. 
Over the last years data accumulated indicating that different classes of antidepressant drugs 
and electroconvulsive therapy exert their effects at least partially via inhibition of LTP, 
mostly mediated via inhibition of NMDA receptors (Anwyl et al., 1987; Stewart and Reid, 
1993; Watanabe et al., 1993; Massicotte et al., 1993; Li et al., 2006; Szasz et al., 2007). 
Moreover, NMDA receptor antagonists have proven to elicit antidepressant-like effects in 
rodents and humans (Rogóz et al., 2002; Zarate, Jr. et al., 2006). In our experiment we could 
not show that the blockade of LTP by activin A is mediated by NMDA receptors. This could 
e investigated. 
d with genetic variants in the activin 
be due to several reasons, like the minor concentrations we used or a NMDA receptor 
independent mechanism. Whether the LTP blockade of activin A is responsible for the acute 
antidepressant-like effects of activin in the forced swim test remains to b
 
Endophenotypes of major depression are associate
signalling pathway 
Using a translational approach, we investigated whether genetic variants (single nucleotide 
polymorphisms, SNPs) in genes involved in the activin signalling pathway are associated with 
specific endophenotypes of major depression in patients. A host of data implicates central and 
peripheral disturbances of stress hormone regulation (hypothalamic-pituitary-adrenocortical 
axis, HPA axis) in the pathogenesis of depression (Holsboer, 2000) and normalization of 
these defects as a prerequisite of clinical response to medication depression (Nemeroff and 
Owens, 2002).  
There is evidence in the literature suggesting an interaction between the activin signalling 
pathway and stress hormone regulation. It was shown that activin A inhibits 
proopiomelanocortin (the precursor of ACTH) mRNA accumulation and ACTH secretion 
from the anterior pituitary, suggesting that locally secreted activins may exert a tonic 
inhibitory influence on pituitary corticotropes (Bilezikjian et al., 1991). Central administration 
of activin A, in contrast, evoked significant elevations of circulating ACTH levels in rats 
(Plotsky et al., 1991). The effects of activin A on HPA system regulation, therefore, seem to 
be more complex and dependent on whether activin A is administered centrally or 
peripherally.  
 76
Results 
In depressed patients, the combined dexamethasone/CRH test is a sensitive test for detecting 
altered HPA system regulation. The outcome in the DEX/CRH test has recently been shown 
to predict antidepressant treatment response in major depression, thus being considered a 
potential biomarker of antidepressant response (Ising et al., 2007). It has been suggested that 
differences in response to antidepressant treatment could be related to innate differences in 
ctivin 
ignalling pathway and altered stress hormone regulation in depressed patients strengthens 
.  
HPA axis regulation (Binder et al., 2004). 
In the present study, we genotyped SNPs in the genes encoding for activin A (Inhba), the 
activin I, IIA and IIB receptors in depressed individuals and found significant associations 
with results in the combined dexamethasone-CRH test: three intronic SNPs located in the 
gene coding for activin A were significantly associated with the ACTH response in the 
dex/CRH test at discharge: individuals carrying the associated genotype GG had more HPA 
hyperactivity. Moreover, in the gene coding for activin receptor IIA (Acvr2a) two SNPs were 
associated with cortisol response at discharge.  
Resolution of depressive symptomatology has been associated with a normalization of HPA 
axis hyperactivity (Holsboer, 2000). The association between genetic variants in the a
s
our preclinical data and emphasizes the potential role of activin signalling in antidepressants’ 
mechanism of action
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 4.  Characterisation of behavioural effects of central gastrin releasing 
 peptide administration 
Depression is a disease with an enormous social and economic burden. It is not simply a 
condition of excessive unhappiness, but core symptoms include insomnia, decreased interest 
in pleasurable stimuli and restlessness (Nestler et al., 2002; Simon, 2003). The 
pathophysiology of the disease is multifactorial and implicates genetic as well environmental 
fore up to 50 times larger than classic neurotransmitters. They exert a 
road spectrum of functions in the brain, ranging from pain transmission and control of food 
take to functions as neurotransmitter, hormones or growth factor (Hökfelt et al., 2003; 
Landgraf and Neumann, 2004). Neuropeptides coexist in most of the cases with at least one of 
the classical messengers, including serotonin and noradrenalin, which are thought to be major 
transmitters implicated in depression and therapeutic effects of antidepressant drugs 
(Chronwall, 1985; Hökfelt, 1991). This aspect proposes them as ideal candidates for 
mediating the pathophysiology of psychiatric disorders. In addition, neuropeptides possess 
more recognition sites for the receptors compared to the smaller classic neurotransmitters and 
contain more chemical information. Consequently, their binding affinity and selectivity is 
enhanced, which means in regard to their pharmacological use for instance less side effects, as 
a smaller amount of antagonists or agonists is needed (Hökfelt et al., 2003).  
Here we used an unbiased approach to identify potential novel drug targets or associations 
between genes and disease. In a previous study Sillaber et al. (submitted, 2007) aimed at 
identifying novel antidepressant-responsive genes in the mouse brain by microarray analysis. 
Mice were chronically treated with the selective serotonin reuptake inhibitor paroxetine and 
subsequent large-scale gene expression profiling in the mouse hippocampus was performed. 
factors (McEwen, 2000a). Available antidepressants are mediating their effects mainly in 
targeting monoamine neurotransmission (Wong and Licinio, 2001). Current 
pharmacotherapies are limited and suboptimal with regard to their tolerability and efficacy 
(Holmes et al., 2003; Nemeroff and Owens, 2002). Regarding the additional delayed onset of 
action of antidepressant treatment, it is not very likely that they directly target causal 
pathways or structures (Taylor et al., 2005). Thus, it is necessary to identify alternative drugs 
that act faster and are more specific. 
To address this question, research over the last years has focused on novel drug targets for 
antidepressant treatment. A main class of identified therapeutic targets was neuropeptides like 
Galanin, Neurokinin 1 or Neuropeptide Y (for review see: Ögren et al., 2006)(Swanson et al., 
2005; Kuteeva et al., 2007; Kramer et al., 1998). Usually neuropeptides are 3-100 amino-acid 
residues long and there
b
in
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Gastrin releasing peptide (Grp) was identified as a potential target gene, as it was significantly 
upregulated after chronic paroxetine treatment. By using in situ hybridisation techniques we 
mory and behaviour (Wada et al., 1997; Roesler et al., 
could confirm a significant increase of Grp mRNA levels in the dentate gyrus region of the 
hippocampus (see project 1). Grp is already known as a gastrointestinal hormone, growth 
factor and neuropeptide (Lebacq-Verheyden et al., 1988). Like several other neuropeptides 
the gastrin releasing peptide is localised in brain areas that mediate affective behaviours and 
responses to stress, like the hippocampus, the amygdala, the thalamus and the hypothalamus 
(Wada et al., 1990). The distribution of the gastrin releasing peptide receptor, a member of the 
G-protein coupled receptor superfamily, is similar to its ligand (Moody and Merali, 2004). 
Furthermore, double-labelling immunohistochemistry revealed already that subpopulations of 
the Grp receptor are present in GABAergic neurons of the amygdala (Kamichi et al., 2005). 
Regarding the functions of gastrin releasing peptide, it exerts a wide spectrum of biological 
effects on metabolism, digestion, me
2006). To date, Grp and its receptor are not well described in correlation with anxiety and 
depression. We hypothesised that the increase in Grp gene expression may at least partially 
underlie the efficacy of chronic antidepressant treatment. To test this assumption, we 
investigated the behavioural effects of a stereotactic infusion of Grp into the hippocampus in 
specific depression and anxiety-related paradigms in vivo (experimental design figure 22). 
 
 
 
Figure 22: Experimental design 
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We wanted to examine the behavioural effects of bilateral microinjections of Grp into the 
dentate, because we had a strong upregulation of Grp in the dentate gyrus of DBA mice after 
chronic paroxetine treatment (see project 1). After investigation of the cannula placement we 
noticed that most of the cannulas terminated in the CA1 region. This deviation might be a 
result of a technical defect of the steretactic apparatus or potentially aberrant head sizes of the 
test animals, which were used to assign the coordinates for the dentate gyrus, compared to the 
animals used in the experiment. Therefore all of our results display the effects of a Grp 
infusion into the CA1 region of the hippocampus. Animals with misplaced cannulas were 
excluded. 
 
Grp injection into the CA1 region had no effects on antidepressant-like behaviour 
We infused Grp (1 μg/side) or 0,9% saline in the CA1 area and tested 30 min after the 
infusion. We could observe no antidepressant-like effects of Grp in the CA1 region in the 
forced swim test, as swimming, struggling and floating behaviour was not significantly 
altered in Grp injected animals compared to the control group (figure 23).  
 
 
Figure 23: 
lateral Grp infusion into the CA1 region showed no significant changes in 
struggling (strug), floating (float) and swimming (swim) behaviour 30 min after treatment. Vehicle group 
n=4; Grp group n=3. Data are presented as mean + SEM. 
Animals that received acute bi
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Figure 24: 
30 min after Grp or saline infusion we could detect no significant differences in the percent time spent on the 
open arm (A) and the total number of head dips (B) on the elevated plus maze, whereas the number of stretch 
attends (C) and rearings (D) was significantly reduced in gastrin releasing peptide infused animals. Vehicle 
group n=4; Grp group n=5. * significant from control group, p<0.05. Data are presented as mean + SEM. 
 intrahippocampal Grp injection on anxiety-related behaviour 
was significantly reduced in mice, that received a Grp infusion (t-test, p<0.05). 
Effects of
We could detect no significant differences regarding anxiety-like behaviour as Grp injected 
animals did not differ in the time spent on the open arm of the elevated plus maze compared 
to the control group (figure 24A). Furthermore, the parameter head dips, which is an indicator 
for anxiety and exploration (Fernández, 1997; Rodgers and Dalvi, 1997), was not 
significantly changed after Grp infusion (figure 24B). However, Grp treated animals 
performed significantly less stretch attends (t-test, p<0.05) (figure 24C), which are associated 
with risk assessment and exploration, and total rears, which display vertical activity (t-test, 
p<0.05) (figure 24D) (Rodgers and Dalvi, 1997). The total distance travelled in the elevated 
plus maze 
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 Effects of intrahippocampal Grp injection on locomotor activity 
In the open field test we reveal a significant difference in general locomotor activity between 
groups. Grp treated animals displayed a significant reduction of locomotor activity compared 
to the control group (t-test, p<0.05) (figure 25A). Consequently, entries and time spent in the 
inner zone of the open field were decreased after Grp infusion (t-test, p<0.05) (figure 25B and 
C). The latency until the first entry into the inner zone was not significantly altered between 
groups, but saline treated animals tend to enter the unprotected area faster than the Grp treated 
mice (t-test, p=0.065) (figure 25D). 
 
 
Figure 25: 
Influence of Grp infusion into the CA1 region of the hippocampus on locomotor activity was measured 45 
min after the treatment in the open field test. There was a significant treatment effect on the locomotion 
regarding the total distance travelled of animals that received Grp infusion into the CA1 region (A). The total 
ntries (B) and time spent (C) in the inner zone of the open field was significantly reduced in Grp number of e
treated mice. There was no significant difference regarding the latency until the first entry into the inner zone 
between groups (D). Vehicle group n=4; Grp group n=5. * significant from control group, p<0.05. Data are 
presented as mean + SEM. 
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Discussion 
In the current study we tested the hypothesis that Grp is directly involved in mediating the 
antidepressant and anxiolytic effects of the selective serotonin reuptake inhibitor paroxetine. 
We tested mice, which received Grp infusion into the CA1 region of the hippocampus in two 
behavioural test paradigms, the forced swim test and the elevated plus maze. In the FST  
antidepressant-like effects of drugs are measured, whereas in the EPM test the anxiety-related 
effects of pharmacological agents are assessed.  
 
Effects of Grp injection into the CA1 region in the forced swim test 
In the forced swim test we could not detect an antidepressant-like effect of Grp treatment 
compared to the control group, as swimming, struggling and floating behaviour was not 
significantly different between both groups. It has already been shown that gastrin releasing 
peptide has an influence on the hippocampal GABAergic system. Grp has been reported to 
depolarise GABAergic interneurons in the stratum oriens layer of the hippocampus and local 
infusion of Grp by reverse dialysis significantly raises levels of GABA in the ventral 
hippocampus (Lee et al., 1999; Andrews et al., 2000). These data suggest a potential 
implication of Grp in the mechanism of action of antidepressant drugs, as deficits in 
GABAergic neurotransmission are supposed to play a role in the aetiology of pathological 
anxiety and mood disorders (for review see: Brambilla et al., 2003)(Earnheart et al., 2007). 
The distinct patterns of gene expression regulation after paroxetine treatment we found in our 
previous studies suggest a highly region-specific function of the investigated genes. As we 
found a strong increase of Grp mRNA in the dentate gyrus and not the CA1 region of the 
hippocampus after chronic antidepressant treatment (project 1), it remains to be investigated 
in a further study whether the infusion of Grp into the dentate gyrus would reveal 
antidepressant-like effects. 
 
Effects of Grp injection into 
T  
c  
n  
and exploration, were decreased in animals that received a Grp infusion. Moreover, the 
comotor activity of the Grp group was significantly decreased. The latter result could be 
confirmed in the open field test. Additionally, Grp treated animals spent significantly less 
time in the inner zone of the open field. This seemingly anxiogenic effects of Grp treatment in 
the CA1 region in the elevated plus maze and the open field test 
esting of Grp treated animals in the EPM revealed no changes in anxiety-related behaviour
ompared to the vehicle treated animals, as the percentage of time spent on the open arm was
ot different between treatment groups. In contrast, parameters, which reflect risk assessment
lo
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 the open field must so far be interpreted as a result of the strongly reduced locomotor and 
ctional Grp signalling decreases locomotion, 
hereas a disconnection of Grp signalling via Grp receptor knockout leads to enhanced 
 might be associated with 
he data from this experiment have to be interpreted with caution for several reasons. In the 
e 
explorative activity of Grp treated mice, because we could not reveal any anxiogenic effects 
of Grp in the elevated plus maze despite altered locomotion.  
There are inconsistent findings regarding the effects of Grp and its receptor on locomotor 
activity. Wada and colleagues reported increased locomotor activity in Grp receptor deficient 
mice during the dark period, the active phase of mice (Wada et al., 1997). These results would 
be in line with our findings, indicating that fun
w
locomotor activity. It has been reported that the altered locomotion
dopaminergic mechanisms, as dopamine receptor antagonists attenuate the generated effects 
on locomotion (Piggins and Merali, 1989). In contrast, other studies could not find effects on 
locomotion in the open field and the elevated plus maze after systemic injection of a Grp 
receptor antagonist, but they could show impaired habituation in the open field (Martins et al., 
2005). Regarding these findings, more research needs to be done to clarify the role of central 
and peripheral Grp signalling. The data support the hypothesis that central and systemic 
administration of Grp might elicit different effects due to different target sites. Moreover, the 
investigation of central Grp should take in account that behavioural effects of Grp infusion 
could be highly dependent on the brain region. Furthermore, there could be a dose-dependant 
effect of Grp, as Mountney and colleagues revealed contrasting results on the expression of 
learned fear after infusion of different doses of Grp into the amygdala (Mountney et al., 
2006). Despite the potential influence Grp on locomotion, several studies have reported that 
central administration of Grp and highly related peptides activates the HPA axis and therefore 
might have downstream effects on antidepressant- and anxiety-like behaviour (Garrido et al., 
1998; Kent et al., 1998).  
 
T
first place our initial intention would have been the investigation of the behaviour of mic
after Grp infusion into the dentate gyrus of the hippocampus, due to our precedent result of a 
prominent increase of Grp in the dentate gyrus after chronic paroxetine treatment. The dentate 
gyrus coordinates we predefined in test surgeries did not work for the experimental animals 
due to potentially aberrant head sizes or maybe a technical defect of the stereotactic apparatus. 
However, most of the cannulas were placed into the CA1 region of the hippocampus and we 
therefore investigated the effects of Grp infusion into the CA1 region in the behavioural 
paradigms. After exclusion of animals with misplaced cannulas only a small number of mice 
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remained per treatment group, which is critical in regard to the achievement of representative 
data. Further, it would be interesting to clarify whether the potential anxiogenic effects of Grp 
in the open field test are really due to locomotor alterations, because in the elevated plus maze 
the altered locomotor activity did not result in altered anxiety-related behaviour. Another 
reason for this discrepancy could be the difference between time point of injection and the 
particular test, as the EPM test was performed 30 min and the open field 45 min after 
injection. It has already been suggested that certain effects of drugs can be dependant on the 
time difference between administration and assessment of data (Khundakar and Zetterstrom, 
2006). Finally, in future studies we should also investigate dose-dependent effects of Grp. 
Flood and colleagues could demonstrate a dose-dependent modulation of memory processing 
after intraperitoneal Grp injection (Flood and Morley, 1988). For our experiment we chose a 
relatively high dose, which might not reflect the normally occurring endogenous Grp 
concentrations and therefore have divergent effects. 
Taken together we could show no antidepressant-like effects in the forced swim test after Grp 
microinfusion into the hippocampal CA1 region. However, we observed a decreased 
locomotor activity in Grp treated mice in the open field and elevated plus maze test. 
Additionally, we found a reduced explorative behaviour after Grp infusion in the elevated 
plus maze. To gain a more detailed insight in the hippocampal functions of Grp a comparison 
of the behavioural effects of Grp microinfusion into the dentate gyrus and the CA1 region 
would be helpful, regarding the fact, that we only had a significant increase of Grp mRNA in 
the dentate gyrus and not the CA1 region after chronic paroxetine treatment.  
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 Discussion 
ajor depressive disorder is a psychiatric disease that is becoming an increasingly important 
oblem in modern society. The World Health Organization estimated that nearly 340 million 
ople are affected by depression worldwide and categorized major depression as among the 
ost disabling clinical diagnosis in the world (Greden, 2001). Moreover, depression has a 
 life of affected people (Üstün et al., 2004). Patients who 
orial disease present a combination of psychological, behavioural 
and physical symptoms like depressed mood, low self esteem, anxiety and insomnia or 
hypersomnia (Nestler et al., 2002). Additionally, affected people have an increased risk of 
mortality as depression aggravates many medical conditions like cardiovascular disease or 
diabetes and causes suicide (Angst et al., 1999; Angst et al., 2002). Many patients have 
recurring episodes of depression and require therefore long-term treatment of their illness 
(Kupfer, 1991). Despite our limited understanding of the underlying pathophysiology of 
depression, there are many effective treatments, as tricyclic antidepressants or selective 
serotonin reuptake inhibitors (Nestler et al., 2002). Still, further knowledge and improved 
treatment strategies are necessary, as 20% of the patients do not respond at all to 
pharmacological or psychotherapeutic treatment and 30% remain symptomatic and disabled 
(Sackeim, 2001). Shortcomings of antidepressant drugs range from intolerable side-effects 
like nausea, somnolence, dizziness and weight gain, to a slow onset of effects (4-8 weeks) 
(Keith, 2006; Gelenberg and Chesen, 2000). Regarding these drawbacks, especially the 
suicidality of patients, there is a desperate need of the development of innovative drugs that 
act faster and more specific.  
Antidepressant drugs primarily modulate monoaminergic neurotransmission. However, the 
latency period of several weeks before the clinical effects of antidepressant therapy occur, 
suggests adaptive neuronal changes following manifold alterations in gene expression, which 
are not necessarily linked to the monoaminergic system (Duman, 1998; Bjartmar et al., 2000). 
Over the last years research is undertaken to identify conceptually novel drug targets or 
pathways. One possible approach is the investigation of genes that respond to antidepressant 
treatment, which may lead to the design of novel substances beyond the “monoamine 
hypothesis” and allow therefore a more successful treatment (Yamada and Higuchi, 2002). 
Although the identification of novel target structures for the treatment of major depressive 
disorder through preclinical research should be considered critically, in the past decades, the 
use of mice in neuropsychiatric research has become more and more important. Besides the 
practical and economic advantages of using mice as they are proficient breeders and can be 
M
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housed in large numbers, the genetic and environmental background and experimental 
daptations mediate the therapeutical effects (Nickel et al., 2003; 
as 
settings are more controllable than in humans (Cryan and Holmes, 2005). Moreover, 
approximately 99% of the mouse genes hold a homologue in the human genome (Waterston 
et al., 2002).  
In this thesis we used an inbred mouse strain (DBA/2), with a high innate anxiety-like 
behaviour (Ohl et al., 2003; Yilmazer-Hanke et al., 2003) to identify and characterise novel 
genes that might be implicated in the action of antidepressant treatment. In a first step we 
were successful in validating the detected regulation of 82% of the selected genes of the 
microarray performed by Sillaber and colleagues (submitted 2007). Considering the 
multifactorial problems of microarray studies in producing reliable data, the validation rate of 
82% is quite high (Asyali et al., 2004). This experiment was mainly conducted to reveal 
potential novel targets for a more direct antidepressant therapy. Subsequently, we were 
interested in the time course and onset of gene expression regulation following different 
periods of paroxetine treatment and the regional specifity of the gene expression changes. 
Therefore, three promising candidate genes were chosen: preproenkephalin 1, tissue 
plasminogen activator and the delta subunit of the GABAA receptor. The potential novel 
antidepressant targets were shown to be selectively and specifically regulated in different 
depression-relevant brain-regions like the hippocampus, the cortex, the amygdala and the 
thalamus in a time-dependent manner. The well-known delay of the onset of action of 
antidepressant drugs (Nemeroff and Owens, 2002) suggests that the primary mechanism of 
action is not the antagonism of serotonin reuptake (Vaswani et al., 2003), but supports the 
hypothesis that downstream a
Thakker-Varia et al., 2007; Abumaria et al., 2007). As we could show that distinct genes 
(Gabrd and Penk1) were already regulated following one week of paroxetine treatment or 
even acutely, these genes could be putative early-responsive targets of antidepressant 
substances. This finding is very interesting in respect to the aim of developing antidepressant 
drugs that act more rapidly than the existing substances. Especially the faster onset of action 
is a desirable attribute for novel drugs regarding the high suicidal tendency of affected 
patients. Only recently Lucas and colleagues could demonstrate that novel serotonin4 (5-HT4) 
receptor agonists exert antidepressant properties at the behavioural and molecular level 
early as after three days of treatment. The observed alterations were comparable to the effects 
of classical antidepressants after two to three weeks of application (Lucas et al., 2007). 
Hopefully, the identification of genes that respond already after a few days of paroxetine 
treatment may lead to the detection of novel pathways, which are causally involved in the 
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 pathophysiology of major depressive disorder and treatment response. To prove the direct 
antidepressant effects of one of our targets we conducted a further experiment in vivo. 
Therefore we chose the activin βA gene and the respective activin A protein, which consists 
of two activin βA subunits. For this gene, a significant regulation could already been shown 
after one week of treatment. The protein is assumed to play a role in neuroprotection and 
neuronal development (Trudeau et al., 1997; Müller et al., 2006). Most of the currently 
available antidepressants are known to increase neurogenesis in the dentate gyrus, what has 
been suggested to be one potential mechanism crucial for antidepressant efficacy (Lesch, 
2001; Duman et al., 2001; Shirayama et al., 2002; Santarelli et al., 2003; Duman and 
Monteggia, 2006). Furthermore, there is evidence to suggest that major depression might be 
induced or accompanied by the activation of inflammatory processes and that antidepressants 
exert their effects through their negative immunoregulatory capacities (Malaguarnera et al., 
1998; Maes, 2001). Inflammation is capable of inducing apoptosis and depression has been 
shown to be accompanied by atrophy of the hippocampus, neurotrophic or neuroprotective 
factors are promising candidates for the treatment and improvement of depressive symptoms 
(Leonard and Myint, 2006; Schmidt and Duman, 2007). For activin A we could clearly show 
an antidepressant-like phenotype in the forced swim test directly after injection into the 
dentate gyrus of the hippocampus of DBA mice. Additionally, the infusion of the protein in 
the amygdala tended to exert anxiolytic effects in the modified hole board test. We performed 
electrophysiological studies on hippocampal mouse brain slices in order to further clarify 
potential underlying neurobiological mechanisms being responsible for the anxiolytic and 
antidepressant-like effects of activin A. We detected that even nanomolar concentrations of 
activin A were able to significantly block hippocampal long-term potentiation (LTP) in the 
CA1 of the hippocampus. Furthermore, we could show that this inhibition is not mediated by 
N-methyl-D-aspartate (NMDA) receptors. In a previous study, Ikegaya and colleagues 
revealed that activin selectively blocks the induction of LTP evoked by threshold tetanic 
stimulation, but not robust LTP elicited by strong tetanic stimulation. This data could indicate 
that activin participates in ‘deciding’ which LTP is essential and selectively excludes 
indefinite LTP (Ikegaya et al., 1997). It has already been shown that, for instance, acute and 
chronic administration of tricyclic antidepressants cause a reduction in the magnitude of LTP 
in hippocampal slices (Watanabe et al., 1993; Massicotte et al., 1993). Moreover, repeated 
electroconvulsive therapy, which is the most effective form of treatment for patients with 
treatment-resistant depression, reduces long-term potentiation in rat hippocampal slices 
(Anwyl et al., 1987; Stewart and Reid, 1993). However, the potential role of hippocampal 
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LTP inhibition in the therapeutic effect of antidepressant drugs remains to be investigated. 
Ultimately, besides the promising data of our preclinical experimental design, we were able to 
identify human genetic variants of the activin family that are associated with distinct 
endophenotypes of depression. Taken together, in this study we were able to bridge the gap 
between basic science (bench) and clinical data (bed), using a translational approach. We 
identified the activin pathway as a potential antidepressant target in mice and could further 
show that genetic alterations in members of the activin family are associated with a distinct 
clinical phenotype.  
As second candidate gene for our in vivo experiments we chose the gastrin releasing peptide. 
There is already evidence that Grp and its receptor might be involved in the neurochemical 
alterations associated with psychiatric disorders (Yamada et al., 2002; Roesler et al., 2006) 
Therefore, we investigated the behavioural effects of Grp infusion into the CA1 region of the 
hippocampus and could not observe an antidepressant-like effect in the forced swim test. 
However, we detected in two other behavioural paradigms (open field and the elevated plus 
maze) a decrease in locomotor activity in mice that had been injected with Grp. This decrease 
in explorative behaviour and risk assessment could indicate a potential anxiogenic effect of 
Grp. Due to several reasons the data from this experiment have to be interpreted with caution. 
A relatively small group size and the Grp-induced alteration of basal locomotor activity 
complicate the interpretation of the behavioural results. Interestingly, the search for a 
corresponding genetic alteration in the Grp gene in patients revealed an association of a 
distinct Grp SNP and an anxious phenotype (data not shown). Regarding the high rate of 
comorbidity between anxiety and depressive disorders, this findings suggest Grp as a 
promising candidate which should be further investigated in detail (Angst, 1996; Kessler et 
al., 1996; Lewinsohn et al., 1997; Mineka et al., 1998; Brown et al., 2001). 
Taken together, in this thesis we could show that a hypothesis-free approach for investigating 
antidepressant-responsive genes in mice provides a promising tool to search for novel 
candidate genes and drug targets. The most fascinating aspect of the study was the possibility 
to bridge the gap between basic research and the human clinical situation. The identification 
of additional and novel genes, which were previously unknown to be implicated in 
antidepressant drug action, will hopefully help to improve the treatment of depression in the 
future.  
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V Summary 
 Summary 
epressive disorders are a highly prevalent public health problem and are a major cause of 
orbidity worldwide. They impinge on the quality of a patients’ life in terms of suffering, 
cial and economic consequences, and increased mortality. Present in all cultural circles they 
fect the complete patients’ environment, including the functioning of the concerned families 
ent of the affected person (Sartorius, 2003). Existing treatments, like 
hotherapy and electroconvulsive therapy, show antidepressant efficacy 
and can significantly improve symptoms of the disease. Unfortunately, the underlying 
pathophysiology of most mood and anxiety disorders has remained unknown so far (Nemeroff 
and Vale, 2005). Consequently, the current available antidepressant substances continue to 
have limitations of both, efficacy and tolerability. The therapy is still hampered by a delayed 
onset of clinical improvement and a series of side effects and relapse is common (Gumnick 
and Nemeroff, 2000; Binder and Holsboer, 2006; Holtzheimer and Nemeroff, 2006). 
Moreover, a substantial group of patients show limited or no response to even the most 
aggressive interventions (Keller et al., 1992; Fink, 2001; Sackeim, 2001). Further, almost half 
of the affected people experience to have residual depressive symptoms despite adequate 
treatment (Fava, 2003). In consideration of these shortcomings, intensive effort is given to 
identify potential novel antidepressant drug targets. High throughput techniques like 
microarray analysis offer the promise to identify novel neurobiological components of 
depressive disorders and antidepressant drug response in a hypothesis-free approach 
(Nemeroff and Vale, 2005).  
In a previous study Sillaber and colleagues analysed the interaction between behaviour, gene 
expression and response to psychoactive substances (Sillaber et al, 2007, submitted). To 
identify novel antidepressant-responsive genes they used DBA/2OlaHsd mice to characterise 
their behaviour under basal conditions and after chronic treatment with the commonly used 
antidepressant paroxetine. In a separate cohort of mice, genechip microarray analysis was 
applied for large-scale gene expression profiling in the hippocampus to investigate 
antidepressant-induced changes in gene expression.  
In project 1 of the present thesis we chose among the regulated genes of the microarray 
analysis eleven genes to further validate and characterise them. After chronic paroxetine 
treatment of mice we performed in situ hybridisation studies on hippocampal brain slices to 
confirm the results of the microarray. 82% of the selected genes could be validated by in situ 
hybridisation: three genes of the activin family, the cholecystokinin B receptor, the delta 
subunit of the GABAA receptor, the gastrin releasing peptide, the glucocorticoid receptor, 
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preproenkephalin 1 and the tissue plasminogen activator. Based on these findings further 
hronic drug application of four weeks in distinct brain regions 
 antidepressant treatment. 
experiments were conducted to characterise those potential novel target genes in more detail 
in vitro and in vivo. 
Project 2 mainly focuses on the detailed time-dependent and regional expression patterns of 
three of the validated candidate genes, namely preproenkephalin (Penk1), tissue plasminogen 
activator (Plat) and the delta subunit of the GABAA receptor (Gabrd). Penk1 is the precursor 
gene of certain endogenous opioid neuropeptides that generate a variety of physiological 
effects like inducing pain relief or modulation of learning and memory (Legon et al., 1982; 
Janecka et al., 2004; Akil et al., 1998). The plasminogen activator protein is a serine protease 
with plasminogen as its primary substrate (Vassalli et al., 1991). It has already been reported 
that the Plat/plasminogen system might play a role in synaptic plasticity (Pang et al., 2004; 
Melchor and Strickland, 2005) and neurotrophic factors in turn are supposed to be implicated 
in the pathophysiology of depression and antidepressant treatment effects (Duman and 
Monteggia, 2006). Finally, we were interested in Gabrd. Most of the fast inhibitory 
neurotransmission in the brain is mediated by GABAA receptors. They consist of a 
combination of five different subunits, which exhibit specific individual expression patterns in 
distinct brain regions and have a unique pharmacological profile (McKernan and Whiting, 
1996; Korpi et al., 2002). The analysis of the time course and onset of gene expression 
regulation in the hippocampus following antidepressant treatment revealed the most 
prominent effects after chronic antidepressant administration. All three genes turned out to be 
significantly regulated after c
(data are shown in project 1). Additionally, gene expression of Gabrd and Penk1 was found 
to be significantly altered already after a subchronic treatment period of seven days, whereas 
Plat mRNA levels were not changed. The only gene that was significantly regulated after 
acute drug application was Penk1; interestingly, the direction of gene regulation after acute 
treatment was in the opposite direction compared to the effects of subchronic and chronic 
treatment. Taken together, we could show that the different genes are regulated in a unique 
time-dependent and region-specific manner following
In project 3 we examined another candidate gene in more detail in vitro and in vivo. Activin 
βA mRNA could also shown to be significantly regulated after chronic (see project 1) and 
subchronic drug application. The respective proteins, the activins and inhibins, are members 
of the transforming growth factor β superfamily and are dimeric proteins composed of α- 
and/or β- subunits (for review see: Luisi et al., 2001; Bernard et al., 2001). In this study we 
investigated the in vivo effects of activin A, which is composed of two activin βA subunits. 
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 There are only a few studies that report on the function of activin A in the central nervous 
system, but it is suggested that it plays a role in neuronal development and neuroprotection 
(Iwahori et al., 1997; Trudeau et al., 1997). To get a more comprehensive overview of 
research and 
behavioural effects of activin A, we stereotactically injected the protein into the dentate gyrus 
or the amygdala of mice and performed specific depression- and anxiety-related behavioural 
tests. We could show that application of activin into the dentate gyrus exerted antidepressant-
like effects, whereas infusion into the amygdala tended to elicit an anxiolytic effect. In a 
following step we were interested in characterising potential underlying neurobiological 
pathways of activin action by performing in vitro electrophysiological analyses. We could 
show that activin is able to significantly block hippocampal LTP. Furthermore, in a large 
cohort of depressive patients, we were able to identify human genetic variants in the activin 
signalling cascade that are associated with a specific endophenotype of depressive disorders. 
The gene we analysed in project 4, the gastrin releasing peptide, was also significantly 
upregulated in hippocampal regions after chronic antidepressant treatment (project 1). As its 
name implies, it can function as gastrointestinal hormone, but also as a neuropeptide or 
growth factor (Lebacq-Verheyden et al., 1988). To examine whether the increase in Grp 
mRNA levels contributes to the efficacy of chronic antidepressant treatment, we investigated 
the behavioural effects of a stereotactic application of Grp into the hippocampus in vivo. In 
the forced swim test no antidepressant-like behavioural phenotype could be observed. Further 
testing in two additional behavioural paradigms that assess anxiety and locomotion, revealed 
a decrease in locomotor activity and risk assessment of Grp treated animals. 
In conclusion, we could show that hypothesis-free approaches, like microarray analysis, are 
valuable for detecting promising candidate genes as potential novel antidepressant drug 
targets. In addition to the data obtained in animal experiments, one candidate gene even 
turned out to be associated with specific endophenotypes of depression and has therefore 
ultimately high clinical relevance. Approaches transferring knowledge from animal studies to 
the clinical situation and back may contribute to uncover the complex and heterogeneous 
genetic background of psychiatric diseases and therefore promote future 
development of antidepressant drugs. 
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List of abbreviations 
 
ACTH   adrenocorticotropic hormone 
Acvr1(a)  activin receptor IA 
Acvr2a  activin receptor IIA 
Acvr2b  activin receptor IIB 
AVP   arginine vasopressin 
BDNF   brain derived neurotrophic factor 
BSA   bovine serum albumine 
CA   cornu ammonis (part of the hippocampal formation) 
Cck   cholecystokinin 
Cckbr   cholecystokinin B receptor 
Chrm1   cholinergic receptor, muscarinic 1, CNS 
CNS   central nervous system 
cpm   counts per minute 
CRH   corticotropin releasing hormone 
CRHR   corticotropin releasing hormone receptor 
DaLi   dark/light box 
Dex   dexamethasone 
DG   dentate gyrus 
ECS   electroconvulsive seizure 
ECT   electroconvulsive seizure therapy 
EPM   elevated plus maze 
fEPSPs  field excitatory postsynaptic potentials 
fMRI    functional magnetic resonance imaging 
FST   forced swim test 
GABA   gamma-aminobutyric acid 
Gabrd   gamma-aminobutyric acid (GABA-A) receptor, subunit delta 
Gmeb1  glucocorticoid modulatory element binding protein 1 
GR (Nr3c1)  glucocorticoid receptor 
Grp   gastrin releasing peptide 
HAM-D  Hamilton Depression Rating Scale 
HPA axis  hypothalamo pituitary adrenal axis 
5-HT   serotonin 
Inha   inhibin alpha 
 Inhba   activin βA/inhibin βA 
tor 
 
ean 
β 
i.p.   intraperitoneal 
LTP   long-term potentiation 
mAChR  muscarinic acetylcholine recep
mHB   modified hole board 
MPI   Max Planck Institute of Psychiatry 
MR   mineralocorticoid receptor 
NaCl   sodium chloride 
NDRI   dopamine reuptake inhibitor 
NMDA  N-Methyl-D-Aspartat 
NRI   noradrenaline reuptake inhibitor 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
Penk1   preproenkephalin 1 
PET   positron emission tomography 
Plat   tissue plasminogen activator  
POMC   preopiomelanocortin 
SEM   standard error of the m
SERT   serotonin transporter 
SNP   single nucleotide polymorphism 
SNRI   noradrenaline reuptake inhibitor 
SSC   sodium chloride-sodium citrate 
SSRI   selective serotonin reuptake inhibitor 
TCA   tricyclic antidepressant 
TGF-β   transforming growth factor 
UTP   uridine triphosphate 
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